

CURICULUM VITAE
July 2010

Maria Francesca Egidi

Office Address: 96 Jonathan Lucas
CSB 829, Charleston SC 29425-6290
Phone: 843-792-6826 **Fax:** 843-792-8399
Citizenship: USA

Education (Beginning with Baccalaureate Degree):

Institution/Location	Years	Degree/Date	Field of Study
University of Milan (Italy)	1970-74	Biological Sciences (July 1974)	Pharmacology
University of Milan (Italy)	1975-81	Doctor of Medicine and Surgery (July 1981)	<i>MagnaCum Laude</i>

Internship: University of Milan (Italy) 1979-81

Residencies or Post Doctoral: University of Milan (Italy) 1982, University of Helsinki (Finland) 1984

Specialty/Board Certification: Nephrology	Date: July 1984
Licensure: Italy (permanent)	Date: since 1981
Iowa	Date: 1991-92
Pennsylvania	Date: 1992-97
Tennessee	Date: 1997-2007
South Carolina	Date: 2007-

Military Service: NA

Faculty Appointments (Begin with initial appointment):

Years	Rank	Institution	Department
2007-	Professor (tenure)	Medical University of South Carolina	Medicine
2000-07	Professor (tenure)	University of Tennessee, Memphis (TN)	Medicine
2002-07	Professor	University of Tennessee, Memphis (TN)	College of Nursing
1997-00	Associate Professor	University of Tennessee, Memphis (TN)	Medicine
1993-97	Associate Professor	University of Pittsburgh, Pennsylvania	Surgery
1992-93	Research Associate	University of Pennsylvania (Philadelphia)	Surgery
1990-92	Visit. Prof.	University of Iowa. Hospitals and Clinics	Surgery/Medicine
1984-94	Assistant Professor	University of Milan (Italy)	Medicine

Administrative Appointments:

Years	Position	Institution	Department
2004-07	Director	Renal Health Center UT/Methodist University	
1999-07	Director	AST Accredited Renal Transplant Fellowship UT/Methodist University	
1997-07	Medical Director	University of Tennessee, Memphis (TN) Transplant Program	
2007-	Medical Director	MUSC Kidney and Pancreas Transplant Program	
2007-	Director	AST Accredited Renal Transplant Fellowship MUSC	

Hospital Appointments/Privileges:

Years	Active/Inactive	Institution
1984-93	Inactive	University of Milan (Italy)
1990-91	Inactive	University of Iowa Hospital and Clinics
1992-97	Inactive	University of Pittsburgh
1997-07	Inactive	University of Tennessee, Memphis
2007-	Active	MUSC

Other Experience:

Years	Position	Institution	Department
1980-82	Post-doc	Pharmacology, University of Milan (Italy)	Biology
1974-89	Researcher	Farmitalia Laboratories	Cardiovascular

Membership in professional/scientific societies (include offices held):

Italian Society of Nephrology	1984
International Transplantation Society	1990
IPITA	1993
West Tennessee NKF Board of Directors	1997
Cell Transplantation Society	1997
American Soc of Transplant Physicians (ASTP)	1998
American Soc of Nephrology (ASN)	2000

Editorial Positions:

Reviewer for:
 America Journal of Transplantation
 American Journal of Kidney Disease
 American Society of Nephrology
 Transplantation
 Transplant International
 Clinical Transplant

Extramural Grants/award amount (current and past):

Funded Grant	Grant Title	Role in Project & Years
1. CNR-Italy (National Research Center)	Immunological monitoring of kidney transplantation	P.I 1986/88

2. University of Tennessee/State of Tennessee: **P.I.** 1999/2000
Management of Post-Transplant Osteoporosis in Women
3. University of Tennessee/UTMG: **P.I.** 2000-2001
Different metabolic patterns of post transplant diabetes mellitus: A prospective study to evaluate the etiology, prevention, and treatment
4. Defining the Immunogeneticity of infiltrating cells in pancreas transplantation
Submitted to Roche Organ Transplantation Research Foundation, **P.I.** 2001
5. A prospective, randomized, multicenter trial of early corticosteroid cessation vs. long term and mycophenolate mofetil. Fujisawa Pharmaceuticals, Co-Inv. 1998-
6. A Randomized Comparative Trial of the effect of antilymphocyte induction on tacrolimus plus mycophenolate mofetil maintenance immunosuppression after simultaneous kidney pancreas transplantation. Fujisawa Pharmaceuticals, Co-Inv. 1998-
7. A Phase III, randomized, double-blind, placebo controlled multicenter study of the efficacy of odulimomab (ANTILFA) in preventing delayed graft function of cadaveric renal allografts in patients not receiving biological induction immunosuppressive therapy. IMTIX, Co-Inv. 1998-1999.
8. Prospective evaluation of consecutive renal allograft recipients receiving a Quadruple, sequential, immunosuppressive Drug Regimen of Thymoglobulin, Sang-35 oral solution (cyclosporine), mycophenolate mofetil, and prednisone. SangStat, Co-Inv. 1998-
9. An Open Label Single Center Comparison Long-Term Generic Cyclosporine Administration in Stable Adult Renal Transplant Recipients. SangStat, Co-Inv. 1998-
10. An Open Label Single Center Comparison of Sandimmune and Generic Cyclosporine Bioequivalence in Stable Adult Renal Transplant Recipients. SangStat, Co-Inv. 1998-
11. Pharmacokinetic and primary prophylaxis with tacrolimus as part of a quadruple, sequential immunosuppressive drug regimen in black cadaveric renal transplant recipients. Fujisawa Pharmaceuticals, Co-Inv. 1998-
13. An open-label, comparative trial of two daclizumab dosing strategies versus no antibody therapy in combination with Tacrolimus, Mycophenolate mofetil, and steroids for the prevention of acute allograft rejection in simultaneous kidney/pancreas transplant recipients. Hoffman-La Roche, Inc, Co-Inv, 1999-
14. Phase II, Open Label, Concentration Controlled Randomized Study of Conventional Dose Tacrolimus Plus Corticosteroids Compared with Reduced Dose Tacrolimus Plus Sirolimus and Corticosteroids in Orthotopic Liver Allografts.” Wyeth-Ayerst, Co-Inv, 2000-
15. Open-Label, Randomized, Multicenter Study to Evaluate the Safety of Zenapax in Combination with Cellcept, Corticosteroids and Standard or Reduced Dose Prograf for the

Prevention of Acute Rejection in Primary Renal Allograft Recipients. Roche, Co-Inv. 2000-

16. An Open-Label, Comparative Trial of Two Dalizumab Dosing Strategies Versus No Induction Treatment in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in Simultaneous Kidney- Pancreas Transplant recipients.” Roche, Co-Inv. 2000-
17. Prospective, Randomized, Multicenter, Double Blind Study of Early Corticosteroid therapy with Zenapax, Prograf, Cellcept in Primary Renal Transplants. Fujisawa , Co-Inv. 2000-
18. Multicenter, Open Label, Exploratory Study to Assess the Safety and Tolerability of Simulect, Neoral, RAD and Steroid for the Prevention of Acute Rejection in Diabetic Patients Undergoing Simultaneous Pancreas-Kidney (SPK) Transplantation. Novartis, Co-Inv. 2000-
19. Pancreatic Islet Cell Transplantation in Humanized NOD-SCID Mice. NIH, Co-Inv. 2000-
20. Pharmacokinetic-Pharmacodynamic Pilot Study of Cytomegalovirus Immune Globulin for the Treatment of Cytomegalovirus Infection.Cytogam, Co-Inv. 2000-
21. Post Treatment Biopsy Study.”Fujisawa , Co-Inv. 2000-
22. Comparison of Sirolimus and Tacrolimus as the Primary Immunosuppressive Agent in Cadaveric Renal Transplant Recipients.Wyeth-Ayerst, Co-Inv. 2000-
23. A phase II, open-label, concentration controlling randomized study of conventional-dose Tacrolimus plus corticosteroids compared with reduced-dose Tacrolimus plus Sirolimus in corticosteroids in orthotopic liver allografts. Wyeth-Ayerst, Co-Inv. 2000-
24. A multi-center, open-label, exploratory study to assess the safety and tolerability of Simulect, Neoral, Rad and steroids for the prevention of acute rejection in diabetic patients undergoing simultaneous pancreas-kidney (SPK) transplantation. Novartis, Co-Inv. 2000-
25. An open-label, comparative trial of Sirolimus in combination with Tacrolimus versus Mycophenolate Mofetil in combination with Tacrolimus for the prevention of acute allograft rejection in simultaneous kidney/pancreas transplant patients receiving Thymoglobulin induction. Wyeth-Ayerst, Co-Inv. 2000-
26. Comparison of Sirolimus and Tacrolimus as the primary immunosuppressive agent in cadaveric renal transplant recipients. Wyeth-Ayerst, Co-Inv. 2000-
28. A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients” Wyeth-Ayerst, **PI**, 2002-
29. A 6- month, multicenter, randomized open-label study to compare the impact of Neoral C2 monitoring on safety and efficacy outcomes in de novo kidney transplant recipients” Novartis, Co-Inv.2002-03

30. A one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus mycophenolate mofetil combined with full dose Neoral and corticosteroids, in de novo adult renal transplant recipients". Novartis, Co-Inv. 2002-
31. A phase II, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the safety and Efficacy of Prograf/FK778 and Prograf/MMF in De Novo Kidney transplant recipients, Fujisawa, Co-Inv 2003-
32. A randomized, open-label study to compare the safety and the efficacy of two different sirolimus regimens with a tacrolimus+ mycophenolate mofetil regimen in de novo renal transplant recipients" Wyeth , Co-Inv. 2003-05
33. A three month, open-label, two cohort study to investigate the safety and tolerability of Myfortic in combination with neoral or tacrolimus in renal transplant recipients with GI intolerance"Novartis, **PI**, 2005-
34. YSPSL (rPSGL-Ig) for the prevention of delayed graft function in cadaveric kidney transplantation. Y's Therapeutics, co-Inv. 2005-
35. A 24-month, multicenter, randomized, open-label non-inferiority of efficacy and safety comparing concentration-controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral versus 1.44 g Myfortic with standard dose Neoral in *de novo* renal transplant recipients, Novartis **PI**, 2006-
36. Evaluation of methods to assess glomerular filtration rate in adult patients with liver disease. Methodist Research Foundation, Co-Inv.2006-
37. A 4-week, multicenter, double-blind, randomized, parallel group study to compare the gastrointestinal safety and tolerability of Myfortic and MMF (Cellcept) when administered in combination with calcineurin inhibitors in renal transplant recipients experiencing gastrointestinal intolerance, Novartis, **PI**, 2006-
38. A phase II, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of Lanthanum Carbonate for the reduction of serum phosphorous in subjects with stage 3 and 4 chronic kidney disease who have elevated serum phosphorous levels. Shire, **PI**, 2006-
39. A Randomized, Placebo,Controlled, Double Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus Wyeth **PI** 2008-
40. Planned Transition to Sirolimus-based Therapy versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients Wyeth, **PI**, 2009-
41. A two part, phase1/2,safety.PK and PD study of TOL101,an anti-TCR monoclonal antibody for prophylaxis of acute organ rejection in patients receiving renal transplantation. Tolera Therapeutics, **PI**, 2010

Intramural Grants/amount of award:

Awards for Scientific Production from Lega per la Rifondazione dell "Ospedale Maggiore di Milano (Italy), 1985

Awards, Honors, Membership in Honorary Societies:

Chaired Cyclosporine Toxicity at the XV Meeting Italian Society for Organ Transplantation, Palermo, 1985

Chaired Glomerulonephritis: Pathophysiology and Treatment at the National Congress Italian Society of Nephrology, Napoli, 1986

Chaired Hystopathology of Kidney Rejection at the XVII National Meeting Italian Society for Organ Transplantation, Cagliari, 1989

Chaired Immunology Session at the XVI International Congress of Transplantation Society in Barcellona, Spain, 1996

Chaired Surgical Complications in Pancreatic Transplantation, 8th World Congress of The International Pancreas and Islet Transplant Association, June 11- 15, 2001, Innsbruck, Austria

Chaired Alloantibody analysis and removal, XIX International Congress of The Transplantation Society, Miami, USA August 27-30, 2002

Chaired How to convert patient to sirolimus, Third International meeting on Sirolimus in renal transplantation, Dublin(Ireland) April 3-4,2003

Chaired How to convert patients to Sirolimus, Fifth International meeting on Sirolimus, Athens (Greece), March 20-21,

Chaired Epidemic of chronic kidney disease symposium (NKF), Memphis (TN) October 15, 2005

Chaired Reconsidering long-term immunosuppression, Six International meeting on Sirolimus :Continuing the quest for improved long-term outcomes in kidney transplantation, Barcelona (Spain) April 4-5,2006

Academic Committee Activities (past 5 years)

University of Tennessee (Memphis)/Methodist University Hospital
College of Medicine
Department Transplant Institute
Division Nephrology/Surgery

University of Tennessee (Memphis)
College of Pharmacy

CURRICULUM VITAE FORMAT (Continued)

Appendix 6

Major Teaching Responsibilities (Current):

Undergraduate Medical Education: NA

Graduate Medical Education:

Master's and Ph.D. Thesis Directed and Postdoctoral Fellows Supervised 1978-1981.
Supervisor of postdoctoral student thesis in pharmacological science. Pharmacology Department, University of Milan.

Teaching activities at Specialty of Nephrology School, University of Parma, 1987.

Teaching activities at University of Milan, Italy, 1986-1989

University of Tennessee (Memphis) Renal Physiology (1998-2003)

Graduate Studies Education: NA

Continuing Medical Education:

Transplant Curriculum Development Meeting, Philadelphia (PA), February 15-16, 2002-06

Transplant Specialist Rapamune Advisory Board Meeting, High Risk Renal Allograft Recipients, Philadelphia (PA), March 15-16, 2002

Transplant Specialist Rapamune Advisory Board Meeting, Clinical Trial Results (Rapamune 210 & 310), Philadelphia (PA), March 25-26, 2002

NKF Task force on diabetes and transplantation, May 6-8, 2003, Chicago (IL)

NKF Task force Living Donor, December 3-4, 2003, Dallas (TX)

Transplantation Innovations and Management Strategies/ An Educational Initiative for Nephrologists: Reducing cardiovascular risks in renal transplant patients. Memphis April 20 and May 8, 2004

Major Clinical Interests and Responsibilities:

Renal and pancreatic transplantation

Fine needle aspiration biopsy for diagnosis of transplant graft rejection.

New immunosuppressive drugs - clinical trials.

Monoclonal antibodies, cytokines and cellular cloning in fine needle aspiration biopsy to study patterns of rejection.

Post transplant diabetes

Post transplant Lymphoproliferative diseases.

Effect of pancreas transplantation on carbohydrate and lipids metabolism

The impact of Hepatitis C virus on transplant population in terms of mortality, morbidity, and renal dysfunction.

Recurrent glomerulopathies in renal transplant recipients

Chronic allograft nephropathy

Desensitization protocols for highly sensitized patients

Living donations: donor and recipient outcomes

BK nephropathy

Lectures and Presentations during the last 3 years – Identify the name and location of the meeting/conference.

Transplant Conference. Renal dysfunction in renal and pancreatic transplantation. National Taiwan University Hospital. September 1, 2003, Taipei (Taiwan)

Transplant Conference. Conversion to sirolimus: indication, guidelines and results in renal and pancreatic transplant recipients. National Taiwan University, September 2, 2003, Taipei (Taiwan)

Transplant Ground Rounds. Renal dysfunction in solid organ transplantation: how to prevent and minimize its progression. Division of nephrology, Taichung Veteran General Hospital, September 2, 2003, Taichung (Taiwan)

Transplant conference. Conversion to sirolimus in solid organ transplant recipients. Urology and Transplant Division September 3, 2003, Taipei (Taiwan)

Primary care and nephrology: Partners in the care of patients with chronic kidney disease. NKF Annual Meeting. Primary care issues in managing long-term recipients of kidney transplants. September 19-20, 2003, Peabody Hotel, Memphis (TN)

Nephrology Conference. Sirolimus in kidney and kidney pancreas transplantation: The status of the art, October 8, 2003, Piedmont Hospital, Atlanta (GA)

Robert J. Corry Pancreas Transplantation Symposium, Invited Lecture: Pancreas transplantation for type II IDDM, October 30-November 1, 2003, Pittsburgh (PA)

ASN, Official Evening Symposium: Invited Lecture: Immunosuppressive strategies in patients with chronic allografts nephropathy, ASN, November 1-18, 2003 San Diego (CA)

Invited lecture: Sirolimus in long-term management of renal and pancreatic transplant recipients. Nordic Sirolimus Summit, November 27-28, 2003, Tromso, Norway

Nephrology Conference. Renal dysfunction in solid organ transplantation. December 17, 2003, University of Texas, S. Antonio TX.

Invited lecture to Australian Rapamycin Launch: Rapamune: Initiation in the maintenance patients, March 13, 2004, Sydney, Australia

Invited lecture at the symposium 'Rapamune: A view to the future', March 14, 2004, Brisbane, Australia

Invited lecture to the Fourth International Symposium on Rapamycin ‘ How to convert patients from calcineurin inhibitors to TOR-inhibitors’ Seville, Spain, March 25-28, 2004

Transplant Grand Round, “Immunosuppressive management in renal and pancreas transplant recipients” Davis University, Sacramento(CA), May 30, 2004

NKF Symposium Living kidney donation: concepts and practices “Evaluation of the living donor”, October 16, 2004, Memphis (TN)

Invited lecture, Pancreas after Kidney Transplantation. Annual S.Raffaele Transplant Meeting, S.Raffaele University Hospital, Milan (Italy), May 19,2005

Transplant Conference, Emerging treatment options in renal transplantation, Mobile (AL), May 27, 2005

Transplant Grand Round, How to Preserve Long-term renal function in transplant recipients, Transplant Institute, Saint Vincent Hospital, Los Angeles (CA), June 5, 2005

Transplant Grand Round, Emerging treatment options in renal transplantation, Cedar Sinai Hospital, Los Angeles (CA), June 6, 2005

Invited lecture, Immunosuppression: The status of the art . Giornate Vastesi di Nefrologia, Vasto (Italy) September 15, 2005

Invited lecture: Breaking the barriers to early transplantation, Epidemic of Kidney Disease, NKF Symposium, Memphis (TN), October 15, 2005

Invited lecture, TOR-Inhibitors, ATS Winter Symposium, Cancun (Mexico), February 15-19, 2006

Invited conference: New paradigms in CKD, Memphis Academy Internal Medicine, Memphis (TN), May 9,2006

Transplant Grand Rounds: The importance of optimizing MPA dosing. Washington Hospital Center, Washington DC, May 23, 2007

Invited lecture: “The Status of the Art of Pancreatic Transplantation” Diabetes Fall Symposium for primary Health Care Professionals, September 10-12, 2008, North Charleston (SC)

Transplant Grand Rounds: “Immunosuppression in kidney transplantation: Timing is critical” Wake Forrest University, Wistom Salem (NC) November 24, 2008

Transplant Grand Rounds: “ Immunosuppression in kidney transplantation: Timing is critical” Tulane University, New Orleans (LA) December 2, 2009

Invited lecture: “What a Primary care provider Needs to Know about Kidney Transplant Patients” 4th Annual Symposium on Management of Chronic Kideny Disease. Charleston (SC) March 14, 2009

Submitted presentations (e.g., abstract or paper presentations)

ABSTRACTS

1. Egidi MF., Sala M., Cesana R., et al. Effetti intestinali della somministrazione intracerebro ventricolare di naloxone nel coniglio sveglio. Abstract Book. 5th Congresso Nazionale dell'Associazione Italiana per lo Studio del Dolore. Perugia, Italy. May, 1981. p. 110.
2. Egidi MF., Colombi M., Radaelli F., et al. Livelli plasmatici di beta-tromboglobulina e trasfusioni piastriniche in pazienti con leucosi acuta. Abstract Book. XXVIII Congresso Nazionale della Società Italiana di Ematologia. Bari, Italy. October 29-31, 1981.
3. Egidi MF., Soriani N., and Ponticelli C. Comportamento delle sottopopolazioni linfocitarie nel trapianto renale. Abstract Book. 1st Incontro su Anticorpi Monoclonali, Milan, Italy. February 25-26, 1983.
4. De Vecchi A., Casati S., Fortina A., Egidi MF., et al. Urolithiasis in renal transplant patients. Abstract Book. XX Congress of EDTA. London. 1983.
5. Egidi MF., et al. Fine needle aspiration biopsy in renal transplantation. *Kidney Int.*, 26:633, 1984.
6. Egidi MF., et al. Fine needle aspiration biopsy in renal transplantation. Abstract Book. XXI Congress of EDTA. Florence, Italy. p 149. 1984.
7. De Vecchi A., Tarantino A., Rivolta E., Egidi MF., et al. Need for steroid in cyclosporine-treated cadaveric renal transplant recipients. Abstract Book XXII. Congress of the EDTA. Brussels. June 22-29, 1985. p. 173.
8. Egidi MF., et al. Comparison of renal biopsy and FNAB in renal transplantation. *Kidney Int.* 29:612. 1
9. Tarantino A., De Vecchi A., Montagnino G., Rivolta E., Egidi MF., et al. Cyclosporine A in renal transplantation. *Kidney Int.* 29:612. 1986.
10. Tarantino A., De Vecchi A., Aroldi A., Montagnino G., Egidi MF., et al. Cyclosporine in (CsA), and methylprednisolone (MP) versus triple therapy: a controlled trial in cadaveric renal transplantation. Abstract Book. X International Congress of Nephrology. London. July 26-31, 1987. p. 6349. 1987.
11. Egidi MF., Stucchi L., Banfi G., et al. The role of fine needle aspiration biopsy in clinical transplantation. Abstract Book. Vth International Workshop on Transplant Aspiration Cytology and Other Non-Invasive Methods of Diagnosis and Rejection. Washington, DC. March 27-29, 1987. p. 1989.
12. Contis J., Brayman KL., Egidi MF., et al. The fate of living donor and cadaver renal allografts in diabetic recipients in the cyclosporine era. 6th Congress of the European Society for Organ Transplantation. Athens, Greece. 1993.
13. Egidi MF., Samimi F., Naji A., et al. Is induction therapy with Anti-T cell antibodies necessary for successful pancreas and kidney transplantation? 6th Congress of the European Society for Organ Transplantation. Athens, Greece. 1993.
14. Contis J., Egidi MF., Naji A., et al. Cox proportional analysis of living and cadaveric renal allografts in diabetic recipients in the cyclosporine era. 6th Congress of the European Society for Organ Transplantation. Athens, Greece. 1993.
15. Brayman KL., Egidi MF., et al. Is mono- or polyclonal induction therapy necessary for successful pancreas and kidney transplantation in the cyclosporine (CyA) era? The Third International Congress on Cyclosporine. Seville, Spain. 1994.
16. Egidi MF., Randhawa P., Pietrzak B., Corry RJ. Fine needle aspiration biopsy (FNAB) in pancreatic transplantation. 5th IPITA Congress. Miami, FL. June 18-22, 1995.

17. Corry RJ., Shapiro R., Vivas C., Scantlebury V., Jordan M., Gritsch HA., Egidi MF. Enteric drainage of pancreas transplants revisited. 5th IPITA Congress. Miami, FL. June 18-22, 1995.
18. Corry RJ , Egidi MF., Shapiro R., et al. Simultaneous pancreas/bone marrow transplantation under FK506 without anti-T cell induction therapy. Abstract Book. American Society of Transplant Surgeons. 21st Annual Scientific Meeting. Chicago, IL. May 14-16, 1995.
19. Zeevi A., Pavlik M., Banas R., Lombardoizzi S., Rao A., Fontes P., Shapiro R., Dodson F., Pham S., Keenan R., Corry R., Egidi MF., et al. An update on immunological monitoring of bone marrow augmented organ transplant recipients. Abstract Book. American Society of Transplant Physicians 14th Annual Scientific Meeting. Chicago, IL. May 14-16, 1995.
20. Shapiro R., Rao A., Fontes P., Demetris A., Trucco M., Zeevi A., Rybka W., Jordan V., Scantlebury V., Vivas C., Gritsch H, Corry RJ., Egidi MF., et al. Combined simultaneous kidney bone marrow transplantation. Abstract Book. American Society of Transplant Physicians 14th Annual Scientific Meeting. May 14-16, 1995.
21. Corry RJ., Egidi MF., Shapiro R., et al. Simultaneous pancreas, kidney, bone marrow transplantation under FK506 without anti-T cell induction therapy. Abstract Book. American Society of Transplant Surgeons 21st Annual Scientific Meeting. Dallas, TX. May 17-19, 1995. p. 75.
22. Zeevi A., Pavlik M., Banas R., Lombardoizzi S., Rao A., Fontes P., Shapiro R., Dodson F., Pham S., Keenan R., Corry R., Egidi MF., et al. An update on immunological monitoring of bone marrow augmented organ transplant recipients. Abstract Book. American Society of Transplant Physicians 14th Annual Scientific Meeting. May 14-17, 1995.
23. Egidi MF., Randhawa R., Pietrzak P., Corry RJ. Fine needle aspiration biopsy in pancreatic transplantation. Abstract Book. Fifth International Congress on Pancreas and Islet Transplantation. June 18-22, 1997. p. 1-2.
24. Corry RJ., Shapiro R., Vivas C., Scantlebury V., Jordan M., Gritsch HA., Egidi MF. Enteric drainage of pancreas transplants revisited . Abstract Book. Fifth International Congress on Pancreas and Islet Transplant. June 18-22, 1995. p. 175.
25. Jordan ML., Shapiro R., Rao A., Fontes P., Demetris A., Trucco M., Zeevi A., Rybka W., Scantlebury V., Vivas CA., Gritsch A., Corry R., Egidi MF., et al. Combined simultaneous kidney/bone marrow transplantation - 3 years experience. Abstract Book. American Urological Association. Orlando, FL. 1996.
26. Shapiro R., Rao A., Fontes., Zeevi A., Demertris AJ., Lyengar A., Trucco M., Jordan M., Scantlebury VP., Vivas C., Gritsch HA., Corry RJ., Egidi MF., et al. Further experience with kidney/bone marrow transplantation. Abstract Book. American Society of Transplant Surgeons. Dallas, TX. May 1996.
27. Corry RJ., Egidi MF., Shapiro R., et al. Pancreas transplantation with enteric drainage under tacrolimus induction therapy. Abstract Book XVI International Congress of The Transplantation Society. Barcelona, Spain. August 25-30, 1996. p. 129.
28. Rao A., Fontes P., Dodson SF., Shapiro R., Corry RJ., Jordan M., Zeevi A., Pham S., Egidi MF., et al. Augmentation of Chimerism with perioperative donor bone/marrow infusion in organ transplant recipients: a three year follow-up. Abstract Book. XVI International Congress of the Transplantation Society. Barcelona, Spain. August 25-30, 1996.
29. Egidi MF., Corry RJ., Kusne E., et al. The incidence of cytomegalovirus disease in pancreas kidney transplant patients in absence of T-cell induction therapy. American Society of Transplant Physicians 15th Annual Meeting. Dallas, TX. May 26-29, 1996. Abstract Book.
30. Zeevi A., Pavlick M., Banas R., Bentejewski C., Spichty K., Rao AS., Fontes P., Demetris AJ., Shapiro R., Jordan M., Dodson SF., Pham S., Keenan R., Griffith B., Corry RJ., Egidi

- MF., et al. Three years of follow-up of bone marrow augmented organ transplant recipients: the impact on donor-specific immune modulation. Submitted. American Society of Transplant Physicians. 18th Annual Meeting. May 15, 1996. p. 164.
31. Rao AS., Fontes P., Dodson SF., Shapiro R., Corry RJ., Jordan M., Zeevi A., Pham S., Egidi MF., et al. Augmentation of chimerism with perioperative donor bone-marrow infusion in organ transplant recipients: a three year follow-up. Abstract Book. XVI International Congress of the Transplantation Society. Barcelona, Spain. May 25-30, 1996. p. 180.
 32. Corry RJ., Egidi MF., Shapiro R., et al. Pancreas transplantation with enteric drainage under tacrolimus induction therapy. Abstract Book. XVI International Congress of the Transplantation Society. Barcelona, Spain. August 25-30, 1996. p. 129.
 33. Egidi MF., Corry RJ., Shapiro R., et al. Enteric-drained pancreas transplants monitored by fine needle aspiration biopsy. Abstract Book. XVI International Congress of the Transplantation Society. Barcelona, Spain. August 25-30, 1996. p. 63.
 34. Stratta RJ., First MR., Egidi MF., et al. Simultaneous use of FK 506 (FK) and mycophenolate mofetil (MMF) in pancreas (PTX) and Kidney Transplant (KTX) recipients: a multicenter report. Abstract Book. XVI International Congress of the Transplantation Society. Barcelona, Spain. August 25-30, 1996. p. 176.
 35. Zeevi A., Pavlick M., Banas R., Bentlejewski C., Spichty K., Rao AS., Fontes P., emetris AJ., Shapiro R., Jordan M., Dodson F., Pham S., Keenan R., Griffith F., Corry RJ., Egidi MF., et al. Three years of follow-up of bone marrow augmented organ transplant recipients: the impact on donor-specific immune modulation. Abstract Book. XVI International Congress of the Transplantation Society. Barcelona, Spain. August 25-30, 1996. p. 259.
 36. Gritsch HA., Egidi MF., Sugitani S., et al. Comparison of azathioprine and mycophenolate mofetil in pancreas transplantation. Abstract Book. Sixth International Congress on Pancreas and Islet Transplantation. October 1997.
 37. Sugitani A., Egidi MF., Corry RJ. Comparison of azathioprine and mycophenolate mofetil in pancreas transplantation. Abstract Book. Sixth International Congress on Pancreas and Islet Transplantation, October 1997.,
 38. Corry, RJ, Egidi, MF., Sugitani, A., Tacrolimus (FK506) without anti-lymphocyte induction therapy prevents pancreas loss from rejection in 100 consecutive patients. Abstract Book. Sixth International Congress on Pancreas and islet Transplantation. Milan, October 1997
 39. Fishbein, T.M., Shapiro, R., Jordan, M.L., Egidi, M.F., Corry, R.J.; Resolution of Hyperglycemia in Pancreas Transplant Recipients Treated with Tacrolimus. Abstract Book. American Society of Transplant Surgeons, 24th Annual Meeting, Chicago, IL, May 1998, p. 228
 40. Jordan, ML, Shapiro R, Egidi, MF, Vivas CA, Scantlebury, VP, Gritsch, HA, Khanna, A, Corry, RJ., Long Term Results of Pancreas Transplantation Under Tacrolimus Immunosuppression. Abstract Book. American Society of Transplant Surgeons, 24th Annual Meeting, Chicago, IL, May 1998, p. 89
 41. Mark L. Jordan, Ron Shapiro, Carlos A. Vivas, Velma P. Scantlebury, H. Albin Gritsch, Francesca Egidi, Ajal Khanna, Robert J. Corry, Long Term Results of Pancreas Transplantation Under Tacrolimus Immunosuppression. Abstract XVII World Congress of The Transplantation Society, July 12-17, 1998
 42. Stratta RJ, First MR, Egidi MF, Corry RJ, Johnson CP, Marsh, CL, Burke GW, Gruessner RGW, Sutherland DER, Kaufman D, Bartlett ST, Slooinger HW, Boudreaux JP, Benedetti E. Simultaneous use of FK506 and mycopenolate mofetil in pancreas and kidney

- transplant recipients: A multicenter reprot. XVI International Congress of the Transplantation Society, August 1996.
43. J Trofe, KS Reddy , TK Somerville, MF Egidi, et al. Ehrlichiosis after Pancreas Transplantation. American Society of Transplant Physicians. 18th Annual Scientific Meeting. May 15-19, 1999, Transplantation 1999: 67 (7) S 98.
 44. Lo A., Alloway RR, Trofe J, Amiri HS, Egidi MF, et al. Outcomes in Solid Organ Transplant Patients Received Granulocyte Colony Stimulating Factor (GCSF) for The Management of Neutropenia. American Society of Transplant Physicians. 18th Annual Scientific Meeting. May 15-19, 1999, Transplantation 1999: 67 (7) S 99.
 45. RR Alloway, T Anderson, D Rye, S Vera, HS Amiri, HP Grewal, RJ Stratta, MF Egidi, et al. One Year Outcomes of Renal Transplant Recipients Receiving SangCya and Neoral. American Society of Transplant Physicians. 18th Annual Scientific Meeting. May 15-19, 1999.
 46. Alloway RR, Lo A, Trofe J, Amiri HS, Egidi MF, et al. Quadruple Therapy with Thymoglobulin (THYMO), SangCya, Cellcept and Steroid in Renal Recipients: Preliminary Results. American Society of Transplant Physicians. 18th Annual Meeting. May 15-19, 1999.
 47. Robert J. Stratta, Francesca Egidi, et al. Analysis of Mortality After Pancreas Transplantation According to Transplant Type, Technique and Immunosuppressive Era American Society of Transplant Physicians. 18th Annual Scientific Meeting. May 15-19, 1999.
 48. Robert J. Stratta, Hosein Shokouh-Amiri, Francesca Egidi, et al. Patterns of Graft Loss After Simultaneous Kidney-Pancreas Transplantation According to Technique and I Immunosuppressive Era. American Society of Transplant Physicians. 18th Annual Scientific Meeting. May 15-19, 1999. Transplantation 1999: 67(7) S 175.
 49. RJ Stratta, MH Shokouh-Amiri, HP Grewal, MF Egidi, et al. A Prospective Comparison of Systemic-Enteric Versus Portal-Enteric Drainage After Simultaneous Kidney-Pancreas Transplantation. American Society of Transplant Physicians. 18th Annual Scientific Meeting. May 15-19, 1999. Transplantation 67(7) S 208.
 50. MF Egidi, et al. Risk Factors for Polyoma Virus: A Comparative Analysis in Kidney-Pancreas and Kidney Transplants. American Society of Transplant Physicians. 18th Annual Meeting. May 15-19, 1999. Transplantation 67 (7) S 222.
 51. LW Gaber, MF Egidi, et al. Focal Mild Intimal Arthritis without Associated Parenchymal Inflammation: Rejection or no Rejection. American Society of Transplant Physicians. 18th Annual Scientific Meeting. May 15-19, 1999. Transplantation 67(7) S 87.
 52. MF Egidi, Trofe J, Stratta RJ, Shokouh-Amiri MH, et al. The Effect of Tacrolimus on the Blood Sugar Control in Pancreas Transplant Patients: A Comparison Among Systemic Enteric, Portal Enteric, and Bladder Anastomosis Techniques. American Society of Transplant Surgeons. 25th Annual Scientific Meeting. May 19-21, 1999. Transplantation 1999: 67(9) S 627.
 53. Shokouh-Amiri MH, Grewal HP, Egidi MF, et al. Pancreas Transplantation with Portal Venous and Enteric Exocrine Drainage: Experiences with 104 Cases. SSAT. May 16-19, 1999.
 54. Stratta RJ, Lo A, Hathaway DK, Winsett RP, Egidi MF, et al. Long-Term Outcome in Simultaneous Kidney-Pancreas Transplant Recipients with Portal-Enteric Drainage. American Society of Transplant Surgeons. May 19-21, 1999.
 55. Stratta RJ, Shokouh-Amiri MH, Egidi MF, et al. Graft Failure after Solitary Pancreas Transplantation. American Society of Transplant Surgeons. May 19-21, 1999.

56. Stratta RJ, Gaber AO, Shokouh-Amiri MH, Grewal HP, Egidi MF, et al. A Single Center Experience with 104 Cases of Pancreas Transplantation with Portal-Enteric Drainage. American Society of Transplant Surgeons. May 19-21, 1999. Transplantation 67(9) S 566.
57. Shapiro R, Jordan ML, Scantlebury VP, Vivas C, McCauley J, Egidi F., et al. Renal Allograft Rejection in Simultaneous Kidney/Pancreas Recipients. Does Dissynchronous Rejection Really Exist? American Society of Transplant Surgeons. May 19-21, 1999.
58. RP Winsett, L. Reed, C. Panicucci, J.Martin, R. Alloway, F. Egidi. Development of Practice Guidelines for the Outpatient Transplant Clinic. Eighth Annual International Transplant Nurses Society Symposium and General Assembly. September 11,1999. Toronto, Ontario, Canada.
59. MF Egidi, et al. Risk Factors for Polyoma Virus (BK): Comparative Analysis in Kidney Pancreas Transplants. 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 102.
60. J Trofe, KS Reddy, TK Somerville, MF Egidi, et al. Ehrlichiosis Infection in Pancreas Transplants. 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 102.
61. MF Egidi, Trofe J, Stratta RJ, et al . Glucose Control in Pancreas Transplants: Comparative Study Among Anastomotic Techniques. 7th World Congress of the International Pancreas and Islet Transplant Association .August 22-25, 1999. Sydney, Australia. Abstract Book Page 72.
62. MF Egidi, Stratta RJ, Trofe J, et al. Is the Native Pancreas More Susceptible to Abnormalities Causing Glucose Intolerance than the Transplant Pancreas? 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 102.
63. Ron Shapiro, Mark L. Jordan, Velma P. Scantlebury, Carlos Vivas, Jerry McCauley Francesca Egidi , et al. Renal Allograft Rejection With Normal Renal Function In Simultaneous Kidney/Pancreas Recipients- Does Dissynchronous Rejection Really Exist? American Society Of Transplant Surgeons. January 15, 1999.
64. Robert J. Stratta, M.H. Shokouh-Amiri, M. Francesca Egidi, et al. Graft Failure After Solitary Pancreas Transplantation. 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 110.
65. Robert J. Stratta, M. H. Shokouh-Amiri, M.F. Egidi, et al. Patterns of Graft Loss After Simultaneous Kidney-Pancreas Transplantation According to Technique and Immunosuppressive Era. 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 94.
66. Robert J. Stratta, A. Osama Gaber, M. Hosein Shokouh-Amiri, Hani P. Grewal, M. Francesca Egidi, et al. A Single Center Experience with 108 Cases of Pancreas Transplantation with Portal-Enteric Drainage. 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 92.
67. Robert J. Stratta, M. Hosein Shokouh-Amiri, Hani P. Grewal, M. Francesca Egidi, et al. A Prospective Comparison of Systemic-Enteric Versus Portal-Enteric Drainage After Simultaneous Kidney-Pancreas Transplantation. 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 55.
68. Robert J. Stratta, M. Francesca Egidi, M. Hosein Shokouh-Amiri, et al. Analysis of Mortality After Pancreas Transplantation According to Transplant Type and Immunosuppressive Era. 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 125.

69. Robert J. Stratta, Agnes Lo, Donna K. Hathaway, Rebecca P. Winsett, M. Francesca Egidi, et al. Long-Term Outcome in Simultaneous Kidney-Pancreas Transplant Recipients with Portal-Enteric Drainage. 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 71.
70. Ron Shapiro, MD, Mark L. Jordan, MD, Velma P. Scantlebury, MD, Carlos Vivas, MD, Jerry McCauley, MD, Francesca Egidi, MD, et al. Renal allograft Rejection with Normal Renal Function in Simultaneous Kidney/Pancreas Recipients - Does Dissynchronous Rejection Really Exist? 7th World Congress of the International Pancreas and Islet Transplant Association. August 22-25, 1999. Sydney, Australia. Abstract Book Page 93.
71. Trofe J, Lo A, Stratta RJ, Vera SR, Grewal HP, Amiri MH, Gaber LW, Alloway R, Gaber AO, & Egidi MF. Redefining the risk factors for development of post-transplant diabetes in liver and kidney transplantation. 17th IDF Congress in Mexico.
72. Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kizilisik TA, Gaber AO. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with Tacrolimus, Mycophenolate Mofetil, and steroids in simultaneous kidney-pancreas transplantation. *Transplant* 2000, May 2000.
73. Gaber LW, Lo A, Egidi MF, Stratta RJ, Shokouh-Amiri MH, Grewal HP, Kizilisik TA, Alloway RR, Gaber AO. Relationship of histological and clinical features of first acute rejection on recurrent rejection and pancreas failure. *Transplant* 2000, May, 2000.
74. Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Alloway RR, Gaber LW, Gaber AO. Outcomes of Simultaneous Kidney-Pancreas Transplantation in African-American Recipients: A Case Control Study. *Transplant* 2000, May, 2000.
75. Gaber LW, Stratta RJ, Lo A, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber AO. Importance of Surveillance biopsy monitoring in solitary pancreas transplant patients receiving Tacrolimus and Mycophenolate Mofetil. *Transplant* 200, May, 2000.
76. Honaker MR, Lo A, Stratta RJ, Egidi MF, Alloway RR, Shokouh-Amiri MH, Gaber LW, Grewal HP, Hardinger KL, Gaber AO. Impact of HCV status in pancreas transplantation : A case controlled study. *Transplant* 2000, May, 2000.
77. Egidi MF, Khan NA, Hardinger KL, Gaber LW, Stratta RJ, Trofe J, Alloway RR, Gaber AO. Redefining the impact of systemic lupus erythematosus on renal allografts: The need for aggressive surveillance. *Transplant* 2000, May, 2000.
78. Egidi MF, Trofe J, Lo A, Stratta RJ, Vera SR, Grewal HP, Shokouh-Amiri MH, Salloum A, Gaber LW, Alloway RR, Gaber AO. Risk factors predisposing liver and kidney transplant patients to the development of post-transplant diabetes. *Transplant* 2000, May, 2000.
79. Shokouh-Amiri MH, Lo A, Hardinger KL, Alloway RR, Trofe J, Grewal HP, Vera S, Stratta RJ, Egidi MF, Anderson T, Kizilisik T, Gaber AO. A low dose, short course of Mycophenolate Mofetil in combination with Tacrolimus after adult liver transplantation. *Transplant* 2000, May, 2000.
80. Honaker MR, Shokouh-Amiri MH, Alloway RR, Grewal HP, Hardinger KL, Kizilisik TA, Bagous T, Trofe J, Vera SR, Egidi MF, Stratta RJ, Gaber AO. Evolving experience of HBV prophylaxis in liver transplant recipients. *Transplant* 2000, May, 2000.
81. Stratta RJ, Shokouh-Amiri MH, Grewal HP, Egidi MF, Kizilisik T, Gaber LW, Gaber AO. Simultaneous Kidney-Pancreas Transplantation with Enteric Exocrine Drainage: A Prospective Comparison of Systemic vs Portal Venous Delivery of insulin. *Society for Surgery of the Alimentary Tract*, May 2000.
82. Stratta RJ, Shohouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Gaber LW, Gaber AO. Simultaneous kidney-pancreas transplant with systemic-enteric versus portal-enteric drainage. XVIII International Congress of the Transplantation Society, August, 2000.

83. Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Alloway RR, Kizilisik AT, Gaber LW, Gaber AO. Limited benefits of anti-IL 2R monoclonal antibody induction in simultaneous kidney-pancreas transplantation. XVIII International Congress of the Transplantation Society, August, 2000.
84. Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Alloway RR, Gaber LW, Gaber AO. Outcomes of simultaneous kidney-pancreas transplant in African-American recipients: A case controlled study. XVIII International Congress of the Transplantation Society, August, 2000.
85. Kizilisik AT, Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Alloway RR, Trofe J, Gaber AO. Ganciclovir prophylaxis for CMV infection in simultaneous kidney-pancreas transplant recipients receiving Tacrolimus, Mycophenolate Mofetil, and Prednisone. XVIII International Congress of the Transplantation Society, August, 2000.
86. Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Alloway RR, Hathaway DK, Gaber L W. A nine year experience with 125 pancreas transplants with portal-enteric drainage. XVIII International Congress of the Transplantation Society, August, 2000.
87. Alloway RR, Lo A, Stratta RJ, Hathaway DK, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber AO. Long-term outcomes in simultaneous kidney-pancreas transplants with portal-enteric versus systemic bladder drainage. XVIII International Congress of the Transplantation Society, August, 2000.
88. Gaber LW, Stratta RJ, Lo A, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kizilisik AT, Gaber AO. Importance of surveillance biopsy monitoring in solitary pancreas transplant patients receiving Tacrolimus and Mycophenolate Mofetil. XVIII International Congress of the Transplantation Society, August, 2000.
89. Shokouh-Amiri MH, Egidi MF, Lo A, Grewal HP, Vera SR, Stratta RJ, Trofe J, Alloway RR, Gaber AO. The importance of early prevention of renal dysfunction in liver transplant recipients. XVIII International Congress of the Transplantation Society, August, 2000.
90. Honaker MR, Shokouh-Amiri MH, Alloway RR, Bagous T, Egidi MF, Grewal HP, Stratta RJ, Vera SR, Gaber AO. Evolving experience of HBV prophylaxis in liver transplantation. XVIII International Congress of the Transplantation Society, August, 2000.
91. Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Shokouh-Amiri MH, Jones M, Vera SR, Grewal HP, Alloway RR, Gaber AO. Post-transplant Lymphoproliferative disorders: A single center experience. XVIII International Congress of the Transplantation Society, August, 2000.
92. Anderson TK, Wood TB, Trofe J, Egidi MF, Gaber LW, Lo A, Alloway RR, Stratta RJ, Gaber AO. Fatal Hemolytic Uremic Syndrome in a Simultaneous Kidney-Pancreas Transplant Patient Receiving Daclizumab, Tacrolimus, Mycophenolate Mofetil and Steroids. International Transplant Nurses Society, Las Vegas, September, 2000.
93. Cashion AK, Acchiardo SR, Egidi MF & Hathaway DK. Factors associated with 24-hour HRV in African-American patients on chronic hemodialysis. ASN, October 13-17, 2000 Toronto, Ontario, Canada.
94. Cashion AK, Acchiardo SR, Egidi MF, Hathaway DK. Factors associated with 24-hr HRV in AA hemodialysis pts. American Autonomic Society in P. Rico October 29-31, 2000.
95. Hardinger KL, Gaber LW, Stratta RJ, Trofe J, Alloway RR, Vera S, Grewal HP, Shokouh-Amiri MH, Gaber AO, Egidi MF. Redefining the impact of recurrent lupus nephritis in renal transplantation. American Society of Nephrology, October, 2000.

96. Hardinger KL, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Honaker MR, Vera S, Alloway RR, Gaber LW, Gaber AO. Renal allograft outcomes in African-American versus Caucasian transplant recipients in the Tacrolimus era. American Society of Nephrology, October, 2000.
97. Chaudhary K, Gaber AO, Stratta RJ, Gaber LW, Alloway RR, Egidi MF. Conversion from Tacrolimus to Sirolimus in kidney and kidney-pancreas transplant recipients. American Society of Nephrology, October, 2000.
98. Trofe J, Gaber LW, Stratta RJ, Reed L, Shokouh-Amiri MH, Alloway RR, Gaber AO, Egidi MF. Polyomavirus in kidney and kidney-pancreas transplant recipients. American Society of Nephrology, October, 2000.
99. Stratta RJ, Gaber AO, Shokouh-Amiri MH, Grewal HP, Egidi MF, Kizilisik TA, Hathaway DK, Alloway RR, Gaber LW. A 9-year experience with 125 pancreas transplants with portal-enteric drainage. Western Surgical Association, November, 2000.
100. Martin JC, Hathaway DK, Egidi MF, Gaber AO. Lifestyle Behaviors affect Cardiovascular risk status of men one year after Kidney Transplantation. International Transplant Nurses Society, Las Vegas, September, 2000.
101. Martin JC, Wicks MN, Hathaway DK, Egidi MF. Health-related lifestyle behavior affect cardiovascular risk status of women one year after kidney transplantation. SNRS 15th Annual Meeting, February 2001. Baltimore, MD.
102. Stratta RJ, Shokouh-Amiri MH, Egidi MF et al. A prospective comparison of simultaneous Kidney-Pancreas transplantation with systemic-enteric versus portal-enteric drainage- The Southern Surgical Association One hundred twelfth annual session - Palm Beach, December 2000- abstract book pg. 19-21.
103. Egidi MF, Cowan PA, Gaber LW, et al. Conversion to Sirolimus: How to determine the optimal window of opportunity. A single center experience. Am J Transplantation, (1): 173 (A150), 2001.
104. Gaber LW, Cowan PA, Egidi MF, et al. Factors associated with histological resolution of acute rejection in kidney transplant recipients undergoing planned paired protocol biopsies. Am J Transplantation, (1): 398 (A1039), 2001
105. KL Hardinger, RJ Stratta, MF Egidi, RA Alloway, et al. Renal allograft outcomes in AA versus Caucasian transplant recipients in the tacrolimus era. Am J Transplantation, (1): 291(A621)2001
106. RJ Stratta, MH Shokouh-Amiri, MF Egidi, et al. Simultaneous Kidney/Pancreas transplantation with portal enteric drainage and tacrolimus/MMF based immunosuppression. Am J Transplantation, (1): 428 (A1159), 2001
107. J Trofe, RJ Stratta, A Lo, LW Gaber, MF Egidi, et al. Thymoglobulin induction or rejection therapy in pancreas transplantation: A single center experience. Am J Transplantation,(1): 428 (A1160), 2001.
108. Stratta RJ, Hardinger KL, Egidi MF, Shokouh-Amiri MH, Grewal HP, Honaker MR, Vera SR, Alloway RR, Gaber LW, Gaber AO. Renal allograft outcomes in African-American versus Caucasian transplant recipients in the Tacrolimus era. Central Surgical Association, March 2001.
109. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Nezakatgoo N, Gaber LW, Gaber AO. Simultaneous kidney-pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetil-based immunosuppression. Eighth World Congress of the International Pancreas and Islet Transplant Association, June, 2001. Acta Chirurgica Austriaca 33 (Supplement); 174:5 (Abstract 01-17), 2001.
110. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Nezakatgoo N, Gaber AO. Improving results in solitary pancreas transplantation with portal-enteric drainage and Tacrolimus/mycophenolate mofetil-based immunosuppression. Eighth World Congress of the

- International Pancreas and Islet Transplant Association, June, 2001. *Acta Chirurgica Austriaca* 33 (Supplement); 174:5 (Abstract 01-17), 2001.
111. Egidi MF, Cowan PA, Stratta RJ, Shokouh-Amiri MH, Grewal HP, Gaber LW, Kizilisik AT, Nezakatgoo N, Gaber AO. Conversion to sirolimus: Preliminary experience in pancreatic transplantation. Eight World Congress of the International Pancreas and Islet Transplant Association, June, 2001. *Acta Chirurgica Austriaca* 33 (Supplement); 174:8 (Abstract 01-29), 2001.
 112. Trofe J, Stratta RJ, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Egidi MF, Alloway RR, Gaber AO. Thymoglobulin induction or rejection therapy in pancreas transplantation: A single center experience. Eighth World Congress of the International Pancreas and Islet Transplant Association, June, 2001. *Acta Chirurgica Austriaca* 33 (Supplement); 174:23-24 (Abstract P1-25), 2001.
 113. Cowan PA, Egidi MF, Stratta RJ, Shokouh-Amiri MH, Grewal HP, Gaber LW, Kizilisik AT, Nezakatgoo N, Gaber AO. Managing conversion to sirolimus: A single center experience in kidney, pancreas and liver recipients. International Transplant Nurses Society, August, 2001.
 114. Kizilisik AT, Stratta RJ, Vera SR, Grewal HP, Shokouh-Amiri MH, Gaber AO, Egidi MF. Risk factors predisposing liver and kidney transplant patients to the development of PTDM. 2001: A Transplant Odyssey, Istanbul, Turkey, August 2001.
 115. Kizilisik AT, Stratta RJ, Gaber LW, Grewal HP, Gaber AO, Egidi MF. Post-transplant lymphoproliferative disorders: A single center experience. 2001: A Transplant Odyssey, Istanbul, Turkey, August 2001.
 116. Kizilisik AT, Gaber AO, Stratta RJ, Shokouh-Amiri MH, Vera SR, Egidi MF. Polyomavirus in kidney and kidney-pancreas transplant. 2001: A Transplant Odyssey, Istanbul, Turkey, August 2001.
 117. Kizilisik AT, Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber AO. Simultaneous KP transplantation with portal enteric drainage and tacrolimus/MMF-based immunosuppression. 2001: A Transplant Odyssey, Istanbul, Turkey, August 2001.
 118. Kizilisik AT, Gaber LW, Stratta RJ, Gaber AO, Egidi MF. Impact of SLE on renal allografts: The need for aggressive surveillance. 2001: A Transplant Odyssey, August 2001.
 119. Kizilisik AT, Stratta RJ, Shokouh-Amiri MH, Grewal HP, Egidi MF, Gaber AO. Thymoglobulin induction or rejection therapy in pancreas transplantation: A single center experience. 2001: A Transplant Odyssey, Istanbul, Turkey, August 2001.
 120. Kizilisik AT, Gaber LW, Stratta RJ, Shokouh-Amiri MH, Gaber AO, Egidi MF. Conversion to sirolimus: How to determine the optimal window of opportunity. A single Center experience. 2001: Transplant Odyssey, Istanbul, Turkey, August 2001.
 121. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Nezakatgoo N, Gaber LW, Gaber AO. Simultaneous kidney-pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetil-based immunosuppression. European Society for Organ Transplantation, October 2001.
 122. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Nezakatgoo N, Gaber LW, Gaber AO. Improving results in solitary pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetil-based immunosuppression with Thymoglobulin induction. European Society for Organ Transplantation, October 2001.
 123. Trofe J, Stratta RJ, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Egidi MF, Alloway RR, Gaber AO. A single center experience with Thymoglobulin in Pancreas Transplantation. *Transplant Immunosuppression 2001. The Complete Care of the Transplant Recipient*, Minneapolis (MN) October 2001.
 124. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Nezakatgoo N, Gaber LW, Gaber AO. Improving results in solitary pancreas transplantation with portal-

- enteric drainage, Thymoglobulin induction, and Tacrolimus/MMF-based immunosuppression. *Transplant Immunosuppression 2001. The Complete Care of the Transplant Recipient*, Minneapolis (MN) October 2001.
125. Lo A, Gaber PL, Egidi MF, Shokouh-Amiri MF, Grewal HP, Vera S, Hollaway MDT, Gaber AO. The etiologies of renal dysfunction under modern immunosuppressive protocols. *ATC*, Washington (DC), May 2002.
 126. Nour B, Egidi MF, Cowan PA, Shokouh-Amiri MH, Gaber AO. Safety and effectiveness of conversion to Sirolimus in liver transplant recipients with renal dysfunction. *ATC*, Washington (DC), May 2002.
 127. Gaber LW, Cowan P, Egidi MF, Honaker M, Aljedai A, Duhart BT, Shokouh-Amiri MH, Vera SR, Grewal HP, Gaber AO. The role of post treatment biopsies in predicting rejection outcome. *ATC*, Washington (DC), May 2002
 128. Egidi MF, Lo A, Cowan P, Shokouh-Amiri MH, Grewal HP, Vera S, Fischer J, Nezakatgoo N, Gaber AO. The impact of the timing of sirolimus initiation and concurrent immunosuppression on serum lipids. *ATC*, Washington (DC), May 2002.
 129. Egidi MF, Gaber L, Cowan PA, Lo A, Shokouh-Amiri MH, Reed L, Rutland T, Gaber AO. Thrombotic microangiopathy in kidney and kidney-pancreas transplant recipients: the impact of different immunosuppressive regimens. *ATC*, Washington (DC), May 2002
 130. Egidi MF, Cowan PA, Gaber LW, Shokouh-Amiri MH, Nezakatgoo N, Fisher J, Gaber AO. Safety and effectiveness of abrupt calcineurin inhibitor discontinuation: A single center experience with conversion to sirolimus. *ATC*, Washington (DC), May 2002
 131. Egidi MF, Cowan PA, Shokouh-Amiri MH, Fisher J, Vera SH, Gaber L, Nezakatgoo N, Gaber AO. Conversion to Sirolimus: Long-term Follow Up in Kidney, Pancreas and Liver Recipients. *ATC*, Washington (DC), May 2002.
 132. Stratta RJ, Egidi MF, Lo A, Shokouh-Amiri MH, Grewal HP, Vera SR, Honaker MR, George C, Gaber LW, Gaber AO. Renal transplantation with variable duration of thymoglobulin induction based on initial allograft function. *ATC*, Washington (DC), May 2002
 133. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Nezakatgoo N, Honaker M, George C, Gaber LW, Gaber AO. Improving results in pancreas transplantation with portal-enteric drainage and Tacrolimus/MMF based immunosuppression. *ATC*, Washington (DC), May 2002.
 134. Lo A, Gaber LW, Abdulkarim B, Egidi MF, Hollaway D, Christenson A, Kelley MS, Gaber AO. Renal Allograft Dysfunction: Pathological Findings and Consequences. *ATC*, Washington (DC), May-June 2003
 135. Lo A, Egidi MF, Gaber LW, Amiri SH, Vera SR, Nezakatgoo N, Christenson A., Kelly MS, Gaber AO. Comparison of two Different Rapamycin Immunosuppressive Regimens In cadaveric renal Transplantation. *ATC*, Washington (DC), May-June 2003
 135. Gaber LW, Lo A, Egidi MF, Gaber AO. Renal Protocol Findings In Patients Receiving Rapamycin Based Immunosuppression With Or Without Low Dose Calcineurin Inhibitor. *AST*, Washington (DC), May-June 2003
 136. Kelley MS, Honaker MR, Egidi MF, Shokouh-Amiri H, Christenson A, Gaber AO. Efficacy Of Low- Dose Vangalciclovir For The Prevention Of CMV After Organ Transplantation, *AST*, Washington (DC), May-June 2003
 137. Honaker MR, Christenson A, Egidi MF, Stratta RJ, Shokouh-Amiri H, Lo A, Gaber LW, Kelly MS, Gaber AO. A Case-Controlled Study Of The Impact Of Hepatitis C Virus Status In Pancreas Transplantation: 3 Year Follow-up. *AST*, Washington (DC), May-June 2003

138. Naseer A, Canada RB, Green CA, Kelley MS, Gaber AO, Shokouh-Amiri H, Nezakgoo N, Egidi MF. Parvovirus B19 Infection In Solid Organ Transplant Recipients: A Single Center Experience. AST, Washington (DC), May-June 2003
139. Duhart BT, Gaber LW, Gaber AO, Shokouh-Amiri H, Nezakatgoo N, Naseer A, Egidi MF. Correlation Between Thymoglobulin Response and Histological findings in Renal Transplantation. AST, Washington (DC), May-June 2003
140. Egidi MF, Shokouh-Amiri H, Gaber LW, George C, Lo A, Naseer A, Fisher J, Nezakatgoo N, Gaber OA. Long-term follow-up in pancreatic transplant recipients converted to Sirolimus IPITA, Dublin July 2003
141. Shokouh-Amiri H, Egidi MF, Gaber LW, Fisher J, Nezakatgoo N, Gaber AO. Long-term results in pancreatic transplantation according to different anastomotic techniques: A single center experience. Transplantation, IPITA, Dublin 2003
142. Lo A, Gross BN, Egidi MF, Gaber AO. Post-transplant diabetes mellitus and sirolimus. American College of Clinical Pharmacy, 2003
143. Lo A, Egidi MF, Gross B, Shokouh-Amiri H, Vera S, Nezakatgoo N, Gaber AO. Sirolimus and mycophenolate mofetil are associated with improved renal function but similar metabolic complications when compared with sirolimus and tacrolimus combination , ATC , May 14-19, 2004, Boston (MA)
144. Lo A, Egidi MF, Gaber AO. Metabolic complications of rapamycin in combination with either tacrolimus or mycophenolate mofetil. ATC, May 14-19, 2004, Boston (MA)
145. Lo A, Walker N, Egidi MF, Gaber AO. Long-term experience with Thymoglobulin induction therapy: malignancy and opportunistic infection. ATC, May 14-19, 2004, Boston (MA)
146. Lo A, Culbreath B, Egidi MF, Cashion A, Gaber AO. The prevalence and incidence of Metabolic complications pre- and post renal transplantation. ATC, May 14-19, 2004, Boston (MA)
147. Lo A, Egidi MF, Shokouh-Amiri H, Vera S, Nezakatgoo N, Gaber LW, Gross B, Dye C, Gaber AO. Does rapamycin really cause delayed graft function? ATC, May 14-19,2004, Boston (MA)
148. Gaber LW, Egidi MF, Lo Agnes, Shokouh-Amiri H, Vera S, Nezakatgoo N, Gaber AO. Renal pathologies in patients receiving rapamycin. ATC, May 14-19, 2004, Boston (MA)
149. Duhart B, Gaber LW, Gaber AO, Shokouh-Amiri H, Nezakatgoo N, Egidi MF. Correlation between Antithymocyte Globulin response and histological findings in renal Transplantation. ATC, May 14-19, 2004, Boston (MA)
150. Showkat A, Lo A, Shokouh-Amiri H, Loheman B, Nezakatgoo N, Gaber AO, Egidi MF. Are autoimmune diseases or glomerulonephritides affecting the development of panel reactive antibodies in candidates for renal transplantation? ATC, May 14-19, 2004, Boston (MA)
151. Egidi MF, Al-Absi A, Mya M et al Emerging treatments for BK- nephropathy: A Single center experience with leflunomide. WTC, July 22-27, 2006, Boston (MA), Abstract Book pag.121
152. Egidi MF, Mya M, Nezakatgoo N, et al. Living donor kidney transplant recipients: Results according to different nephrectomy techniques. WTC, July 22-27, 2006, Boston (MA)
153. Gaber LW, Shokouh-Amiri H, Saharia A, Egidi MF et al. Early protocol biopsies in African-American patients following kidney transplantation WTC, July 22-27, 2006, WTC, July 22-27, 2006, Boston (MA), Abstract Book pag.674
154. Patel SJ, Moore LW, Krauss AJ, Duhart BT, Scarborough OD, Mya M, Egidi MF and Gaber AO. Delayed graft function does not confer worse renal outcomes at one year in patients receiving thymoglobulin induction. WTC, July 22-27, 2006, Boston (MA)

Abstract Book pag.651

155. Shokouh-Amiri H, Saharial A, Nezakatgoo N, Egidi MF et al. Uretro-ureterostomy as treatment of choice for ureteral reflux and repeated urinary tract infections in kidney transplant recipients. WTC, July 22-27, 2006, Boston (MA), Abstract Book pag.451
156. Egidi FM, Moore M., Mya M., Babu K, Nezakatgoo N, Vera RS, Krauss A and Eason J. Non-suitable kidney living donors (NSD): A Single Center Retrospective Analysis. American Transplant Congress, May 5-7, 2007, San Francisco (CA).
157. Patel SJ, Duhart BT, Krauss AG, Moore LW, Egidi MF et al. Differences in risk factors for acute rejection between African-American and non African-American renal transplant recipients under Antithymocyte Globulin Induction. AJT, 2007;7(S2):445 (Abstract #1198)
158. Duhart TB, Patel SJ, Krauss AG, Nezakatgoo N, Saharia A, Gaber AO, Eason J, Egidi MF. Can modern immunosuppression ameliorate racial differences between African-American and Caucasian kidney transplant recipients? 3 year results. AJT,2007; 7(S2):519 (abstract#1448)
159. Weimert NA, Taber DJ, Baliga P, Bratton CF, Chavin KD, Lin A, McGillicuddy W, Ayiku H, Egidi MF et al. Predictors of proteinuria following sirolimus conversion: Analysis of a large, single center experience. American Transplant Congress, May 31-June 4, 2008, Toronto (Canada)
160. Weimert NA, Taber DJ, Baliga P, Bratton CF, Chavin KD, Lin A, McGillicuddy W, Ayiku H, Egidi MF et al. Conversion in African American versus Non-African American kidney transplant recipients : Analysis of long-term patient and allograft outcomes. American Transplant Congress, May 31-June 4, 2008, Toronto (Canada)
161. Weimert NA, Taber DJ, Baliga P, Bratton CF, Chavin KD, Lin A, McGillicuddy W, Ayiku H, Egidi MF et al. Does de novo proteinuria following sirolimus conversion predict allograft loss ? Analysis of a large, single center experience. American Transplant Congress, May 31-June 4, 2008 Toronto (Canada)
162. Kuppachi S, Miles L, Mugambi S, Baliga P, Egidi MF. Halted living kidney donors. A retrospective analysis of medical and social reasons. Submitted to Renal Week Meeting, ASN, San Diego, 2009 (CA)
163. Kuppachi S, Wiggins K, Self S, Egidi MF. Are kidney transplant biopsies useful for directing the treatment in case of positive polyomavirus (BK) viremia and normal renal function? Submitted to Renal Week Meeting, ASN, San Diego, 2009 (CA) Accepted as a Poster
164. Egidi MF, Kuppachi S, Wiggins K, Carstens E. Does diabetes have a role in Polyomavirus nephropathy development? Submitted to IPITA 2009, Venice (Italy) Accepted as Oral presentation
165. Egidi MF, Kuppachi S, Miles L, Mugambi S. Un-expected number of halted living kidney donors: A retrospecitve aanlysi of medical and social reasons. Submitted to 2009 Organ Doation Congress, Berlin (Germany) Accepted as a Poster
166. Kuppachi S, Sanders D, Carstens E, Egidi MF. Impact of ureteral reflux on recurrent urinary tract infections and graft survival. Submitted to ATC 2010, San Diego (CA)
167. Kuppachi S, Mugambi S, Miles L, Egidi MF. Halted living kidney donors. A retrospective analysis of medical and social reasons. Submitted to ATC 2010, San Diego (CA)

Publications:

1. Ponticelli C., Rivolta E., Egidi F., Caglio C., and De Vecchi, A. Il trapianto renale in eta' pediatrica Proceeding of Giornate Internazionali di Como: Progressi e Problemi Attuali in Pediatria, Villa Olmo, Italy, September 29-30, 1982.
2. De Vecchi A., Tarantino A, Rivolta E., Egidi F., et al. Studio controllato di 2 diversi schemi di terapia steroidea nel trapianto renale da cadavere. 2nd Middle European Meeting on Dialysis and Transplantation, Gorizia, Italy, September 30 - October 2, 1982, p.201.
3. Ponticelli C., Egidi F., De Vecchi A., and Corbetta C. Cyclosporine in renal transplantation. Attualita' nefrologiche e dialitiche 1983. Wichtig, Milan. p 205. 1983.
4. Ponticelli C., De Vecchi A., Tarantino A., Rivolta E., Egidi F., et al. A search for optimizing corticosteroid administration to renal transplant patients. *Kidney Int.*, 23 (Suppl. 14):85-89, 1983.
5. Tarantino A., Egidi F., Rivolta E., et al. Neoplasie e trapianto renale. *Minerva Nefrologica Suppl. Monografico* 30(No. 2):37-40, 1983.
6. Egidi F., Vecchi A., Petrucci E., et al. Monitoraggio del trapianto renale con aspirazione con ago sottile (AAS). *Nefrologia. Trapianto, Dialisi*, 1983:445-456. 1983.
7. Egidi F., De Vecchi A., Rivolta E., Soriani N., and Ponticelli C. Effetto delle diverse terapie antirigetto sulle sottopopolazioni linfocitarie di pazienti sottoposti a trapianto renale. Proceedings of the IIIrd Convegno di Nefrologia e Dialisi, Bardonecchia, Italy, March 24-25, 1983: 261-262, 1983.
8. Egidi F., De Vecchi A., Petrucci A., and Ponticelli C. Valutazione citologica dell'infiltrato infiammatorio del rene trapiantato tramite aspirazione con ago sottile. Proceedings of the IIIrd Convegno di Nefrologia e Dialisi, Bardonecchia, Italy, March 24-25, 1983: 273-274, 1983.
9. De Vecchi A., Egidi F., Rivolta E., Tarantino A., and Ponticelli C. Comparison of fine needle aspiration biopsy and core biopsy in renal transplantation. *Renal Transplant Cytology*, Wichtig, Milan, p. 81, 1984.
10. Egidi F., De Vecchi A., Rivolta E., Caglio G., and Ponticelli C. Preliminary experience of 110 fine needle biopsies (FNAB) in renal transplant patients. *Renal Transplant Cytology*, Wichtig, Milan, p. 81, 1984.
11. Egidi F., De Vecchi A., Tarantino A., et al. La "fine needle aspiration biopsy" nel monitoraggio del trapianto renale in pazienti trattati con ciclosporina. *Nefrologia, Dialisi, Trapianto* 1983, Wichtig, Milan, p. 379, 1984.
12. De Vecchi A., Egidi F., Tarantino A., et al. La ciclosporina nel trattamento dei pazienti trapiantati di rene da cadavere. *Nefrologia, Dialisi, Trapianto* 1983, Wichtig, Milan, p.381, 1984.
13. Graziani G., Egidi F., Morganti A., Sala C., et al. La stimolazione dopaminergica nel rene trapiantato. *Nefrologia, Dialisi, Trapianto* 1983, Wichtig, Milan, p. 383, 1984.
14. Rivolta E., De Vecchi A., Egidi F., et al. La ciclosporina nel trapianto da cadavere 5th Congresso Nazionale della Societa' Italiana de Trapianto d'Organo, Sirchia A. and Notari D., eds., p.83, 1984.
15. Egidi F., De Vecchi A., Rivolta E., Soriani N., and Ponticelli C. Effects of different antirejection treatments on lymphocyte subsets in renal transplantation. *La Ricerca XIV* (No. 3):341-344, 1984.
16. Egidi F., De Vecchi A., Rivolta E., Tarantino A., and Ponticelli C. Cyclosporine in cadaveric renal transplantation. *Int. Journal-Bulletin of the European Institute of Ecology and Cancer (INEC)*, 12:3-5, 1984.
17. Egidi F., Monitoraggio del trapianto renale mediante aspirato cellulare. *Giornale Italiano di Nefrologia*, 1:29, 1984.

18. Egidi F., Banfi G., et al. Studio comparativo della biopsia renale e dell'aspirato cellulare nel trapianto renale. *Nefrologia, Dialisi, Trapianto* 1984, Wichtig, Milan, p. 357-1985.
19. Egidi F., Studio dell'aspirato cellulare in trapiantati renali con diversi regimi immunosoppressivi. *Nefrologia, Dialisi, Trapianto* 1984, Wichtig, Milan, p. 361, 1985.
20. Tarantino A., De Vecchi A., Montagnino G., Rivolta E., Egidi F., et al. La ciclosporina nel trapianto renale da cadavere. *Nefrologia, Dialisi, Trapianto* 1984, Wichtig, Milan, p. 407, 1985.
21. De Vecchi A., Tarantino A., Rivolta E., Egidi F., et al. Sono necessari gli steroidi nei pazienti trapiantati di rene trattati con ciclosporina? *Nefrologia, Dialisi, Trapianto* 1984, Wichtig, Milan, p. 415, 1985.
22. Rivolta E., Tarantino A., De Vecchi A., Egidi F., et al. L'OKT3 nel trattamento del rigetto resistente agli steroidi. *Nefrologia, Dialisi, Trapianto* 1984, Wichtig, Milan, p. 423, 1985.
23. Graziani G., Passerini P., Egidi F., et al. Funzione paratiroidea dopo trapianto renale. In *Iperparatiroidismo ed alluminio*, Wichtig, Milan, p. 29, 1985.
24. Imbasciati E., Banfi G., Egidi F., et al. Quadri morfologici nel rigetto nel trapianto renale. *Attualità Nefrologiche e Dialitiche*, Wichtig, Milan, p. 39, 1985.
25. Egidi F., et al. La biopsia con ago sottile nel monitoraggio del rene trapiantato Dialisi oggi -No 6, Anno II:49, 1985.
26. Egidi F., De Vecchi A., Pagliari B., et al. Lack of relationship between blood cyclosporine levels and nephrotoxicity at FNAB. *Proc. EDTA*, 22:579, 1985.
27. Rivolta E., De Vecchi A., Tarantino A., Egidi F., et al. Rescue of steroid-resistant rejection with OKT3 PAN. *EDTA*, 22:677, 1985.
28. Egidi F., De Vecchi A., Banfi G., et al. Comparison of renal biopsy and fine needle aspiration biopsy in renal transplant. *Transplant. Proc.* XVII(1):61, 1985.
29. Ponticelli C., De Vecchi A., Egidi F., et al. Management of the nephrotoxicity of cyclosporine in cadaveric renal transplant recipients. *Transplant. Proc.*, XVII(2):61, 1985.
30. De Vecchi A., Zanella Z., Egidi F., and Ponticelli C. Autoimmune hemolytic anemia in a cadaveric transplant patient treated with cyclosporine. *Acta Haematologica*, 73:216, 1985.
31. Egidi F., Tarantino A., De Vecchi A., et al. Patterns of inflammation in fine needle aspiration biopsy in renal transplant. *Transplant. Proc.*, XVII(5):2091-2093, 1985.
32. Egidi F., De Vecchi A., Pagliari B., et al. Lack of relationship between blood cyclosporine levels and nephrotoxicity assessed by fine needle aspiration biopsy. *Transplant Proc.*, XVII(5):2096-2097, 1985.
33. Rivolta E., De Vecchi A., Tarantino A., Egidi F., et al. Treatment of acute rejection of human renal allograft by OKT3 Pan. *Int. J of Immunopharmacology*, 1985:405, 1985.
34. Rivolta E., Tarantino A., De Vecchi A., Egidi F., et al. Gli anticorpi monoclonali nel trapianto di rene. *Giornale Italiano di Nefrologia*. 3:87, 1986.
35. Rivolta E., De Vecchi A., Tarantino A., and Egidi F. Significato prognostico dell'antigenemia HBs nel trapianto renale da cadavere. *Nefrologia, Dialisi, Trapianto* 1985, p. 67, 1986.
36. Egidi F., Rivolta E., Tarantino A., et al. Caratterizzazione degli infiltrati linfocitari nel rene trapiantato. *Nefrologia, Dialisi, Trapianto* 1985, Wichtig, Milan, p. 43, 1986.
37. De Vecchi A., Rivolta E., Tarantino A., Egidi F. et al. Controlled trial of two different methylprednisolone doses in cadaveric renal transplantation. *Nephron*, 41:262-266. 1986.
38. De Vecchi A., Tarantino A., Rivolta E., Egidi F., et al. Need for steroid in cyclosporine treated cadaveric renal transplant recipients. *Transplant. Proc.*, XVIII:999, 1986.
39. Tarantino A., De Vecchi A., Montagnino G., Egidi F., et al. Cyclosporine in renal transplantation. *Cont. Nephrol.*, 51:88, 1986.

40. De Vecchi A., Tarantino A., Rivolta E., Egidi F., et al. Cyclosporine alone or associated to steroids for immunosuppression of cadaveric renal transplant? *Cont. Nephrol.*, 51:88, 1986.
41. Ponticelli C., Rivolta E., Tarantino A., Egidi F., et al. Clinical experience with Orthoclone OKT3 in renal transplantation. *Transplant. Proc.*, XVIII:942, 1986.
42. De Vecchi A., Tarantino G., Montagnino G., Egidi F., et al. A controlled prospective trial of triple therapy with low dose azathioprine, cyclosporine and methylprednisone in renal transplantation. *Transplant. Proc.*, XIX:1933, 1987.
43. Egidi F., Banfi G., Bogetic J., et al. Correlation between fine needle aspiration and renal biopsy in renal transplantation. *Transplant. Proc.*, XX(4):589-591, 1988.
44. D'Amico G., Colasanti G., Barbiano di Belgiojoso G., Fellin G., Ragni A., Egidi F., et al. La glomerulonefrite a depositi IgA. Follow up a lungo termine in 374 pazienti. *Giornale Italiano di Nefrologia* 5(No. 1):29-34, 1988.
45. Egidi F., Banfi G., Bogetic J., et al. Correlation between fine needle aspiration and renal biopsy in renal transplantation. *Transplant. Proc.*, XX(4):589-591, 1988.
46. Egidi F. La biopsia renale con ago sottile. *Attualita; Nefrologiche e Dialitiche*, 1987:89-93, 1988.
47. Egidi F., Renal fine needle biopsy. *Cont. Nephrol.*, 69:81-86, 1989.
48. Egidi F., Stucchi L., and Montagnino G. The Role of fine needle aspiration biopsy in clinical transplantation. *Transplant. Proc.*, 21(4):3576-3577, 1989.
49. Togni E., Travaglini P., Beretta C., Beradinelli L., Vegeto A., Mocchegiani E., Egidi F., et al. Prolactin, thymulin and zinc in chronic hemodialysis: effect of renal transplant. *Jei* 13(9)709-15, 1990.
50. Egidi F. Fine needle aspiration biopsy in renal transplantation: A review of cytologic features. *Diagnostic Cytopathology*, 6(5):330-335, 1990.
51. Egidi F., Stucchi L., Cantu MA., and Ponticelli C. Cellular infiltrates during different immunosuppressive regimens in renal transplantation. *Transplant. Proc.* 23(1):1115-1116, 1991.
52. Egidi F., Scott D., and Corry RJ. The effect of transfusions on renal allograft survival in the cyclosporine era: a single center report. *Clinical Transplantation*, 7:240-243, 1993.
53. Brayman K.L., Egidi MF., Naji, et al. Is induction therapy necessary for successful simultaneous pancreas and kidney transplantation in the cyclosporine era? *Transplant. Proc.*, 26:5:2525-2527, 1994.
54. Egidi MF., Shapiro R., Khanna A., et al. Fine needle aspiration biopsy (FNAB) in pancreatic transplantation. *Transplant, Proc.* , 27(6) pp 3055-3056, 1995.
55. Corry RJ., Egidi MF., Shapiro R., Jordan R., Gritsch HA., et al. Enteric drainage of pancreas transplants revisited. *Transplant. Proc.* 27(6) pp 3048-3049, 1995.
56. Shapiro R., Rao AS., Fontes P., Zeevi A., Jordan M., Scantlebury VP., Vivas C., Gritsch HA., Corry RJ., Egidi MF., et al. Combined simultaneous kidney/bone marrow transplantation. *Transplantation* 60(12) pp 1421-1425, 1995.
57. Shapiro R., Rao AS., Fontes P., Zeevi A., Jordan M., Scantlebury VP., Vivas C., Gritsch HA., Corry RJ., Egidi MF., et al. Kidney/bone marrow transplantation. *Dialysis and Transplantation* 25(5) 282-287, 1996.
58. Rao As., Fontes P., Zeevi A., Rugeles M., Shapiro R., Jordan M., Corry R., Egidi MF., et al. Enhancement of donor cell chimerism in whole organ allograft recipients by adjuvant bone marrow. *Transplant. Proc.* 27(6) 3387-3388, 1995.
59. Sugitani A., Gritsch AH, Egidi MF., Corry RJ. En-bloc pancreas and kidney transplantation using vascular access. *Transplantation* 63:1683-1701, 1997.
60. Gritsch AH., Shapiro R., Egidi MF., et al. Spontaneous arterio-enteric fistula following pancreas transplant. *Transplantation* 63(6):903-904. March, 1997.

61. Egidi MF., Corry RJ., Sugitani A., et al. Enteric-drained pancreas transplants monitored by fine needle aspiration biopsy. *Transplant. Proc.* 29:674-675. 1997.
62. Rao A., Fontes P., Dodson SF., Shapiro R., Corry RJ., Egidi MF., et al. Augmentation of chimerism with perioperative donor bone-marrow infusion in organ transplant recipients: a three year follow-up. *Transplant. Proc.* 29:1184-1185. 1997.
63. Corry RJ, Egidi MF., Shapiro R., et al. Pancreas transplantation with enteric drainage under tacrolimus induction therapy. *Transplant. Proc.* 29:642. 1997.
64. Zeevi A., Pavlick M., Banas R., Bentlejewski C., Spichty K., Rao AS., Fontes P., Demetris AJ., Shapiro R., Jordan M., Dodson F., Pham S., Llull R., Keenan R., Griffith B., Corry RJ., Egidi MF., et al. Three years of follow-up of bone marrow augmented organ transplant recipients: the impact on donor-specific immune modulation. *Transplant. Proc.* 29:1205-1206. 1997.
65. Stratta RJ, First MR, Egidi F., et al. Simultaneous use of FK 506 and mycophenolate mofetil in pancreas transplant recipients: A multicenter report. *Transplant. Proc.* 29:654-655. 1997.
66. Gruessner RWG, Gruessner A, Sutherland DER, Egidi F., et al. Tacrolimus in pancreas transplantation: A multicenter analysis. *Clinical Transplantation* 11:299-312. 1997.
67. Gritsch HA, Egidi MF., Sugitani A., et al. Comparison of azathioprine and mycophenolate mofetil in pancreas transplantation. *Tranplantat Proc*1998,30:526.
68. Sugitani A., Egidi MF., Gritsch HA., et al. Serum lipase as a marker for pancreatic allograft rejection. *Transplant Proc.* 1998, 30:645.
69. Corry RJ, Egidi MF., Sugitani HA., et al. Tacrolimus (FK506) without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. *Transplant Proc.* 1998, 30:521.
70. Sugitani A., Gritsch HA., Shapiro R., Bonham CA., Egidi MF., Corry RJ. Surgical complications in 123 consecutive pancreas transplant recipients: comparison of bladder and enteric drainage. *Transplant. Proc.*, 1998; 30,293-294.
71. Sugitani A., Egidi MF., Gritsch HA., Corry RJ.; Serum lipase as a marker for pancreatic allograft rejection; *Clinical Transplantation* 1998;12,224-227.
72. Jordan, ML, Shapiro R, Vivas CA, Scantlebury, VP, Gritsch, HA, Egidi, MF., Khanna, A, Corry, RJ., Long Term Results of Pancreas Transplantation Under Tacrolimus Immunosuppression. *Transplantation* 1999; 67 (2), 266-72.
73. Corry, R.J., Shapiro, R., Egidi, M.F., Jordan, M.L, Scantlebury, V., Vivas, C., Gritsch, H.A. and Starzl, T.E. Pancreas Transplantation Without Antibody Therapy. *Transplant. Proc.*, 3, 299-300, 1998.
74. Reddy, K.S., Stratta, R.J., Shokouh-Amiri, H., Alloway R.A., Sommerville T., Egidi, M.F., et al. Simultaneous Kidney-Pancreas Transplantation Without Anti-Lymphocyte Induction. *Transplantation* 2000; 69, 49-54.
75. Stratta RJ, Gaber AO, Shokouh-Amiri MH, Reddy SK, Egidi MF., et al. Allograft Pancreatectomy After Pancreas Transplantation: A Comparison of Systemic-Bladder versus Portal-Enteric Drainage. 1999. Proceeding Book of the 3rd World Congress of the I.H.P.B.A.
76. Stratta RJ, Gaber AO, Shokouh-Amiri H, Reddy KS, Alloway RR, Egidi MF., et al. Evolution In Pancreas Transplantation Techniques: Simultaneous Kidney-Pancreas Transplantation Using Portal-Enteric Drainage Without Antilymphocyte Induction. *Ann Surgery* 1999, 229, (5)701-711.
77. Robert J. Stratta, A. Osama Gaber, M. Hosein Shokouh-Amiri, K. Sudhakar Reddy, M. Francesca Egidi. Hani P. Grewal. Allograft Pancreatectomy After Pancreas Transplantation with Systemic-Bladder Versus Portal-Enteric Drainage. *Clinical Transplantation* 1999: 13(6): 465-472.

78. Stratta RJ, Gaber AO, Shokouh-Amiri MH, Reddy S, Egidi MF et al. A Prospective Comparison of Systemic-Bladder Versus Portal-Enteric Drainage In Vascularized Pancreas Transplantation. 1999.Surgery 127: 217-226, 2000.
80. Shapiro R, Jordan ML, Egidi MF, et al. Renal allograft rejection with normal renal function in simultaneous kidney/pancreas recipients. Transplantation. 2000, 69, (3), 660-661.
81. Trofe J, Reddy KS, Egidi MF, Shokouh-Amiri MH, Gaber AO, Stratta RJ. Human Granulocytic Ehrlichiosis in Pancreatic Transplant Recipients. Transplant Infectious Disease 2001, (3):34-39.
82. Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Trofe J, Alloway RR, Gaber LW, Gaber AO. Patters of Cytomegalovirus Infection in Simultaneous Kidney-Pancreas Transplant Recipients Receiving Tacrolimus, Mycophenolate Mofetil, and Prednisone with Ganciclovir Prophylaxis. Transplant Infectious Disease 2001, (3):8-15
83. Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO. Outcomes of Simultaneous Kidney-Pancreas Transplantation in African-American Recipients: A Case Controlled Study. Clinical Transplantation 2000, 14 (6): 572-579.
84. Lo A, Stratta RJ, Trofe J, Egidi MF, Shokouh-Amiri MH, Grewal HP, Alloway RR, Gaber AO. Rhodococcus Equi Pulmonary Infection in a Pancreas Alone Transplant Recipient: Consequence of Intense Immunosuppression. Transplant Infectious Disease 2002; 4:46-51
85. Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO. Limited Benefits of Induction with Monoclonal Antibody to Interleukin-2 Receptor in Combination with Tacrolimus. Mycophenolate Mofetil, and Steroids in Simultaneous Kidney-Pancreas Transplantation. Transplant Proc., 2001, (33):1701-1703.
86. Egidi MF, Cowan P, Gaber LW, Shokouh-Amiri MH, Stratta RJ, Vera SH, Nosratollah Nezakatgoo, Gaber AO. Indications and Clinical Guidelines from Calcineurin Inhibitors to Sirolimus Conversion: A Single Center Experience. Transplantation, in press 2002.
87. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Gaber LW, Gaber AO. Simultaneous kidney-pancreas transplant with systemic-enteric versus portal-enteric drainage. Transplant Proc 2001, (33):1661-1662.
88. Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HO, Kizilisik AT, Alloway RR, Gaber AO. Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients: A case control study. Transplant Proc 2001, (33): 1675-1677.
89. Lo A, Stratta RJ, Egidi MF, Kizilisik AT, Shokouh-Amiri MH, Grewal HP, Trofe J, Alloway RR, Gaber AO. Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone. Transplant Proc 2001, (33): 1796-1798.
90. Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Alloway RR, Hathaway DK, Gaber LW. A nine-year experience with 125 pancreas transplants with portal-enteric drainage. Transplant Proc 2001, (33): 1687-1688.
91. Lo A, Stratta RJ, Lo A, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kizilisik AT, Gaber AO. Long term outcome in simultaneous Kidney-Pancreas transplant recipients with portal-enteric versus systemic-bladder drainage. Transplant Proc 2001, (33): 1684-1686.
92. Gaber LW, Stratta RJ, Lo A, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kizilisik AT, Gaber AO. Role of surveillance biopsies in monitoring recipients of pancreas alone transplants. Transplant Proc 2001, (33): 1673-1674.
93. Shokouh-Amiri MH, Egidi MF, Lo A, Grewal HP, Vera SR, Stratta RJ, Kahn NA, Trofe J, Alloway RR, Gaber AO. The importance of early prevention of renal dysfunction in liver transplant recipients. Transplant Proc 2001, (33): 1399-1400.

94. Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Shokouh-Amiri MH, Jones M, Vera: Post-transplant Lymphoproliferative disorders: A Single Center Experience. *Transplant Proc* 2001, (33): 1838-1839.
95. Hardinger KT, Stratta RJ, Egidi MF, Alloway RR, Shokouh-Amiri MH, Gaber LW, Grewal HP, Honaker MR, Vera Santiago, Gaber AO. Renal Allograft Outcomes in African-American versus Caucasian Transplant Recipients in the Tacrolimus Era. *Surgery* 2001;130(4):738-45
96. Martin JC, Hathaway DK, Egidi MF, Gaber AO. Lifestyle behaviors affect cardiovascular risk status in men one year after Kidney Transplantation. *Clinical Transplant* 2001;15(6):41-5
97. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Nezakatgoo N, Gaber LW, Gaber AO. A prospective comparison of simultaneous kidney-pancreas transplantation with systemic-enteric versus portal-enteric drainage. *Ann Surg* 233:740-751, 2001.
98. Alloway RR, Gaber AO. Long-term Outcomes in Simultaneous Kidney-Pancreas Transplant Recipients with Portal-Enteric vs Systemic-Bladder Drainage, *Am J Kid Dis* 38: 132-143, 2001.
99. Egidi MF, Cowan PA, Naseer A, Gaber AO. Conversion to sirolimus in solid organ transplantation: a single center experience. *Transplant Proc* 2003; 35 (S3):131-7
100. Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. *Transplant Int* 2001;14 (16): 396-404
101. Stratta RJ, Gaber AO, Shokouh-Amiri MH, Grewal HP, Egidi MF, Kizilisik AT, Hathaway DK, Gaber LW. A 9-year experience with 126 pancreas transplants with portal-enteric drainage. *Arch Surg* 2001;136(10):1141-9
102. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber AO. Pretransplant and immediate post-transplant considerations for solitary pancreas transplantation. *Diabetes Spectrum* 2001
103. Honaker MR, Shokouh-Amiri MH, Vera SR, Alloway RR, Grewal HP, Hardinger KL, Kizilisik AT, Bagous T, Trofe J, Stratta RJ, Egidi MF, Gaber AO. Evolving Experience of HBV Prophylaxis in Liver Transplantation. *Transpl Infect Dis* 2002; 4(3): 137-143
104. Honaker MR, RJ Stratta, Lo A, Egidi MF, Shokouh-Amiri MH, Grewald HP, Alloway RR, Gaber LW, Hardinger KL, Gaber AO. Impact of hepatitis C virus status in pancreas transplantation: A case controlled study. *Clinical Transplant* 2002; 16 (4):243-51
105. Lo A, RJ Stratta, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with Tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. *Transpl Int* 14(2001) 6, 396-404.
106. Al-jedai A, Honaker MR, Trofe J, Egidi MF, Gaber LW, Gaber AO, Stratta RJ. Renal allografts loss due to Polyomavirus interstitial nephritis after simultaneous kidney-pancreas transplantation: results with kidney retransplantation. *Transplantation* 2003;75 (4): 490-4
107. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, George C, Gaber LW, Gaber AO. Improving results in pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetil-based immunosuppression. *Am J Transplant*, 2(3), 203:257, 2002.
108. Egidi MF, Cowan PA, Shokouh-Amiri MH, Fisher J, Vera SH, Gaber LW, Nazakatgoo N, Gaber AO. Conversion to sirolimus: Long-term follow-up in kidney, pancreas and liver recipients. *Am J Transplant*, 2(3), 274:540, 2002.

109. Gaber AO, Egidi MF, Lo A, Gaber LW, Shoukough-Amiri HP, Grewal RJ, Stratta S, Fischer VJ, Anderson T. Defining the optimal doses of sirolimus and Tacrolimus in high-risk cadaveric renal transplantation recipients. *Am J Transplant*, 2(3), 274:541, 2002.
110. Egidi MF, Gaber LW, Cowan PA, Lo A, Shoukough-Amiri MH, Reed L, Rutland T, Gaber AO. Thrombotic microangiopathy in kidney and the kidney-pancreas transplant recipients: The impact of different immunosuppressive regimens. *Am J Transplant*, 2(3) 405:1059, 2002.
111. Nour B, Egidi MF, Cowan PA, Sebastian A, Shoukough-Amiri MH, Vera SH, Gaber AO. Safety and effectiveness of conversion to sirolimus in liver transplant recipients with renal dysfunction. *Am J Transplant*, 2(3), 463:1293, 2002.
112. Stratta RJ, lo A, Shoukough-Amiri H, Egidi MF et al. Improving results in solitary pancreas transplantation with portal-enteric drainage and thymoglobulin induction *Transplant Proc.*2002;34(5), 1915-7
113. Egidi MF, Cowan PA, Gaber LW, Shoukough-Amiri MH, Nezakatgoo N, Fisher J, Gaber AO. Safety and effectiveness of abrupt calcineurin inhibitor discontinuation: A single center experience with conversion to sirolimus. *Am J Transplant*, 2(3), 470:1316, 2002.
114. Egidi MF, Cowan PA, Gaber LW, Reed L, Rutland T, Shoukough-Amiri MH, Vera S, Gaber AO. Abrupt calcineurin-inhibitor discontinuation with sirolimus conversion: A single center experience. *Transplantation*, 74(4), 98:259, 2002.
115. Egidi MF, Lo A, Cowan P, Shoukough-Amiri, Grewal HP, Vera S, Fisher J, Nezakatgoo N, Gaber AO. The impact of the timing of sirolimus initiation and concurrent immunosuppression on serum lipids. *Transplantation*, 74(4), 433:2143, 2002.
116. Gaber LW, Cowan PA, Egidi MF, Honaker M, Al-jedai A, Duhart BT, Shoukough-Amiri HP, Vera SR, Gaber AO. Role of post treatment biopsies in predicting rejection outcome. *Transplantation*, 74(4), 458:2280, 2002.
117. Lo A, Gaber LW, Egidi MF, Shoukough-Amiri HP, Grewal SR, Vera S, Hollaway DT, Gaber AO. The etiologies of renal dysfunction under modern immunosuppressive protocols. *Transplantation*, 74(4), 664:3315, 2002.
118. Stratta RJ, Lo A, Shoukough-Amiri MH, Egidi MF, Gaber LW, Gaber AO. Improving results in solitary pancreas transplantation with portal-enteric drainage, thymoglobulin induction, and Tacrolimus/mycophenolate mofetil-based immunosuppression. In press, *Transplant Int* 2003; 16(3): 154-60
119. Stratta RJ, Shoukough-Amiri MH, Egidi MF, Grewal HP, Lo, A, Kizilisik AT, Nezakatgoo N, Gaber LW, Gaber AO. Long-term experience with simultaneous kidney-pancreas transplantation with portal-enteric drainage and Tacrolimus/mycophenolate mofetil-based immunosuppression. *Clinical Transplant* 2003; 17 (9): 69-77
120. Gaber L, Egidi MF, Reed L, Nezakatgoo N, Fisher J. Polyomavirus-Nephropathy (PVN):Determine of Graft Loss. *J.Am.Soc. Nephrol.*2002, 13:178A
121. Trofe J, Gaber LW, Shokouh-Amiri MH, Vera SR, Alloway RR, Lo A, Gaber AO, Egidi M.F. Polyomavirus in kidney and kidney-pancreas transplant recipients. *Transpl Infect Dis* 2003, 5:21-28
122. Egidi MF, Gaber AO. Outcome of African-American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. *Transplantation* 2003; 75:572-573
123. Shokouh-Amiri H, Egidi MF, Gaber LW, Fisher J, Nezakatgoo N, Lo A, Gaber AO. Long-term results in pancreatic transplantation according to different anastomotic techniques: A single center experience. *Transplantation*, 2003; 76 (4): S19
124. Gaber LW, Egidi MF, Lo A, Gaber AO. Renal pathology findings and clinical presentations of polyomavirus-nephropathy in kidney-pancreas transplant recipients compared to kidney transplant recipients. *Transplantation*, 2003; 76 (4): S 56
125. Lo A, Egidi MF, Gaber LW, Shokouh-Amiri H, Nazakatgoo N, Fisher J, Gaber AO.

- Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. *Clin Transplant* 2004; 18: 53-61
126. LoA, Egidi MF, Gaber LW, Shokouh-Amiri H, Vera S, Neazakatgoo N, Gaber AO. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free Regimens in cadaveric renal transplantation. *Transplantation* 2004;77 (8):1228-35
 127. Gaber LW, Egidi MF, Lo A, Gaber AO. Renal pathology and clinical presentation of polyomavirus nephropathy in simultaneous kidney-pancreas transplant recipients compared with kidney transplant recipients *Transplant Proc.*2004;36(4):1095-6
 128. Lo A, Egidi MF, Gaber LW, Gaber AO. Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients. *Transplant Proc* 2003; 35 (S3): 103-8
 129. Trofe J, StrattaRJ, Egidi MF, LoA, Gaber LW, Shokouh-Amiri H, Grewald HP, Honaker Hardinger K, Alloway RR, Gaber AO. Thymoglobulin for induction or rejection therapy in pancreas allografts recipients: a single center experience. *Clin Transplant* 2002; 16 (7):34-44
 130. Showkat A, Lo A, Shoukou-Amiri H, Nezakatgoo N, Gaber AO, Mya M, Egidi MF. Are autoimmune diseases or glomerulonephritis affecting the development of panel-reactive antibodies in candidates for renal transplantation? *Transplant Proc.* 2005;37(2): 645-7
 131. Gaber LW,Egidi MF, Stratta RJ et al. Clinical utility of histological features of polyomavirus allograft nephropathy, *Transplantation*, 2006; 82(2):196-204
 132. Patel SJ, Duhart BT, Krauss AG, Moore I, Egidi MF, Shokouh-Amiri H, Gaber LW, Gaber AO. Risk factors and consequences of delayed graft function in high-risk cadaveric renal transplant patients receiving rabbit antithymocyte globulin induction. *Transplantation* 2008; 86 (2): 313-20
 - 133.McGillicuddy J, Weimert NA; Taber D, Turner A, Mitchell L., Wray D, Egidi MF et al. Preemptive CMV Monitoring Be As Effective As Universal Prophylaxis When Implemented As The Standard of Care?" *Transplantation*, 2009; 89 (10):1218-23
 - 134.Patel N, Taber DJ, Weimert NA, Fleming JN, Egidi MF et al. Potential differences in kidney allograft outcomes between ethnicities when converting to sirolimus base immunosuppression. *Transplant Proc.*2009;41 (10): 4131-7
 - 135.Fleming JN, Taber DJ, Wiemert NA, Egidi MF et al. Comarison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. *Transpl Int.*2010; 23 (5):500-5
 - 136.Hammond EB, Taber DJ, Weimert NA, Egidi MF et al. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. *Clin Transplant.*2010;24(1):40-7

Chapters in Scholarly Books and Monographs

1. Ponticelli C., Montagnino F., Banfi G., Tarantino A., De Vecchi A., Egidi F. Renal impactof cyclosporine in patients with kidney transplant. *Napredak u transplantaiji organa.* p 26-33. 1986.
2. Rivolta E., De Vecchi A., Tarantino A., Egidi F., et al. Signification prognostique de l'antigenemie Hbs dans la transplantation renale da cadavre. **Transplantation and Clinical Immunology XVIII: Risk Factors in Organ Transplantation.** Touraine, Traeger J., Beutel H., Dubernard JP., Triau (Eds.) Excerpta Medica, Amsterdam. p 338. 1986.
3. Egidi F., Stucchi L., Montagnino G., et al. Eight years experience with fine needle aspirationbiopsy in clinical transplantation. **Transplantation, and Clinical Immunology**

- XVIII: Risk Factors in Organ Transplantation.** Touraine J., Traeger J., Betuel H., Dubernar JM., Revillard JP., Triau R., (Eds). Excerpta Medica, Amsterdam. p 521. 1986.
4. Brayman KL., Egidi MF., Naji A., et al. Renal transplantation at the University of Pennsylvania Medical Center: an update of results in the cyclosporine era. **Clinical Transplants.** 1992 Terasaki P., Ed. UCLA Press. Los Angeles, CA. 20:215-225.
 5. Shapiro R., Jordan ML., Scantlebury VP., Vivas C., Gritsch HA., Rao AS., Trucco M., Zeevi A., Demetris AJ., Randhawa P., Corry RJ., Egidi MF., et al. Renal transplantation at the University of Pittsburgh: the impact of FK506. **Clinical Transplants, 1994.** Eds. Terasaki and Cecka. UCLA Tissue Typing Laboratory. Los Angeles, CA. p 229-236. 1995.
 6. O'Connor TP., Egidi MF., Brennan PJ., et al. Diagnosis and treatment of rejection, infection, and malignancy in transplant recipients. **Intensive Care Medicine.** Third Edition. Eds. Rippe J., Irwin R., Fink M., Cerra F. Little, Brown and Company. 1996.
 7. Egidi MF., Corry RJ. Simultaneous kidney/pancreas transplantation. **Current Opinion in Organ Transplantation.** Rapid Science Publishers. Ed Ryan. Philadelphia, PA. p44. 1996.
 8. Corry, Robert J, M. Francesca Egidi, Bowles Steven: Pancreas Transplantation; **Fourth Edition Textbook of Critical Care**, (edited by W. Shoemaker, A. Grenvik, S. Syres, P. Holbrock); W.B. Saunders Company, 1998, Chapter 183, pp. 1982-1986
 9. Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi M.F., et al. Experience with Portal-Enteric Pancreas Transplantation at the University of Tennessee-Memphis. **Clinical Transplants.** 1998. Cecka and Terasaki, Eds., Chapter 22, pp. 239-253.
 10. Gaber AO, Wicks MN, Stratta RJ, Gaber LW, Amiri H, Hathaway DK, Egidi M.F. Pancreas-Kidney Transplantation In Diabetic Uremic Patient: An Overview In: **Clinical Nephrology, Dialysis and Transplantation.** An updated test (eds) Malluche et al. 1999. Chapters 3-8 pp. 1-26.
 11. Egidi M.F., Fine Needle Aspiration Biopsy in Pancreatic Transplantation: **Pancreas Transplantation**, In: Corry RJ, Shapiro R, Eds. Marcel Dekker Inc. New York, NY, 2006
 12. Egidi M.F. Medical Management in Pancreas Transplantation. **Pancreas Transplantation**, In: Corry RJ, Shapiro R, Eds. Marcel Dekker, Inc. New York, NY, 2006
 13. Stratta RJ, Shokouh-Amiri MH, Egidi M.F., et al. Experience with portal-enteric pancreas transplantation at the University of Tennessee, Memphis. **Pancreas Transplantation.** In: Corry RJ, Shapiro R, Eds. Marcel Dekker, Inc. New York, NY, 2006
 14. Stratta RJ, Shokouh-Amiri MH, Egidi M.F., et al. Experience with portal-enteric pancreas transplantation at the University of Tennessee, Memphis. **Clinical Transplants.** 2001. Eds. Cecka and Terasaki, Eds. Chapter 19, pp. 217-223
 15. Gaber LW and Egidi M.F., Surveillance and monitoring of pancreas allografts. **Current Opinion in Organ Transplantation** 2002, 7:191-195
 16. Egidi MF, Cowan PA, Gaber AO. Conversion to Sirolimus in solid organ transplantation: A single center experience. In "Ten Years of Sirolimus Therapy", Barry D. Kahan Ed. **Transplantation Proceedings** 2003, 35 (suppl 3A), 131S-137S
 17. Lo A, Egidi MF, Gaber LW, Gaber AO. Observations on the use of Sirolimus and Tacrolimus in high risk renal transplant recipients. In "Ten Years Experience of Sirolimus Therapy", Barry D. Kahan Ed. **Transplantation Proceedings**, 2003, 35 (suppl 3A), 105S-108S
 18. Egidi M.F Management of hyperglycemia after pancreas transplantation: Are new immunosuppressant the answer? **Drugs** 2005,65(2);153-166
 19. Egidi MF. Prevention and management of hyperglycemia after pancreas transplantation. **Current Opinion in Organ Transplantation**, 2008,13 (1): 72-78
 20. Egidi MF. Post-transplant Glucose Intolerance in "**Pancreas, Islets and Stem cell**

transplantation for the treatment of diabetes” (second edition) ,Edited by
Nadey Hakim, Robert Stratta , Derek Gray, Peter Friend and Alan Colman
Oxford University Press, in press 2009